2022-06-30-accounts

British Society for immunolog Annual Report 2022

| Trustees, Report For the year ended 30 June 2022 What we do and why it rnatters The 8rltlsh Soclety for Immunology is the award winning (Best Overall A$50clation 2020, The Associatlon Awards) and leading UK membership organisation worklng with scientists and cllnicians from academia and industry to fonNard immunology research and application around the world. Our frlendly, accesslble community con51sts of over 4.3Cil immunolo8i5tS, giving us a powerful volce to advocate on Immunological sclence and health for the beneflt of society. The Soclety supports Its members, students and the wlder publlc to learn more about Immuno108Y through disseminatin8 research and providin8 resources, activities and grants to aid education in this fleld. Immunological science underplns many aspects of human and animal health and disease, from communicable disease and vacclnation to the management and treatment of many chronic condltlons. Through enhanclng our knowled8e of how the lrnmune system funrtlons for the publlc benefit, the Brit15h Society for Immunolo8y can play a key role In advanclng Socletls ablllty to prevent and treat d15ease. Our mlsslon The British Society for Immunolog￿5 rni55ion 15 to promote excellence in immunological research, scholarshlp and clinlcal practlce in order to Improve human and anlmal health. We accomplish this by.. Worklng wlth our members to support current and future 8eneratlons of ImmunoloBiSts. Sharlng our passion for Immunology through meetlngs. publications and the medla. Bulldlng up aTr under5tandin8 of our work by engaging wlth the public and those worklng In the research and health environments. Worklng with partners In pursuit of our misslon, building on common interests The Trustees confimi they have referred to the Charity Commission's guidance on public benefit when reviewing the Soclety's aims and objeclives, plannin8 future actlvitles and settlng the annual operating plan,

Our strateglc oblectlves The British society for Immunolo8V Strategy sets our direction and priorlties for 2021-2025. Building on the strong foundations of our past work and guided by our updated vlslon and mlsslon statements and set of values. this ambktlous strategy lays out how we will work with our membership to deliver for the immunology and wider community over the coming years. As the UK'S leading charity and scientific society representing the Immune research sector. we are confident that we will fulfil this strate8y to lead a positive change towards our vlslon of better health for all through Immunologv. We arecommltted to wpportl our lrnmunulDyy comrnunltyln dr￿Ing 5tlentlFl¢ dls(o¥*ry and maklng a po￿tIve lrnpact on healih To prfvidp th 1mnlunolo￿ ioinrnuDiry mtrrtr connoctihiil and Enablers Membershlp Flth•nci•l Stability Dfv•rslty & Incluslon

Connected communlty Our BSI community is at the heartofall we do. Beinga member ofthe BSI means bein83 memberof one of the largest immunology networks in the world. Immunology 15 a growing field, and the BSI aims to continualty develop our activities and the support we provide to members to enable the dlscipline to flourlsh. Immunology intersects with numerous research field5, acr055 different sedors. with the involvement of all career 8rades. Our 8oal is to bring this ecosystem together Into a cohesive whole that fvlflls our mi551on to take immunologry forwards faster and more collaborative￿, Membership of the British Society for Immunology brlngs many benefits. These Include discounts to our meetin8s and to our exceptional BSI Congress, access to a diverse range of grants, bursaries and prizes, free acce5S to ourjournals and much more. The Society provides tailored support for our community through our highly valued Regional and Affinity Groups, but we are also there to represent immunolo8y to the wider world. Members value our stron8 voice to speak out wlth influence and Impact on behalf of Immunolo8y in pollcy. publlc engagement and the medla. At the end of June 2022, we had over 4,31XI members who loln us from all walks of immunologv. From students up to senior levels, they contribute to our work through many different routes, Includlng speaklng at our conferences, helpin8 wlth our publlc engagement activlties and advising on our policy work- our grateful thanks go to our whole immunology communlly, In December 2021, over 1,61XI Immunologlsts came together In Édlnburgh and onllne for our fl4g5hlp event, BSI Congress. It was an amazing four days of Immunology, packed with cutting*dge science, inspiring debates and those much-missed opportunltle5 to connect and start new collaboratlons. Thls year. we kept our onllne attendance optlon which proved popular wlth those who did not feel comfortable attendin8 in person or who couldn't get time away from work. Feedback from delegates WJs very posltlve, wbth many pralslng the scientific content, the networklng opportunlties afforded to attendees and the Inclusive nature of the event. Absiiart submlsslons Over 2000 Blind reviews 94 36 594 Sessions Posters 816, Orals 61

BS121

immunolog

An amazing 97% of dele8ates Stating they would recommend the BSI Congress to colleagues. We look forward to welcomin8 the immunology communty back to LNerpool for the 2022 BSI Congres5. Reglonal and Affinlty Groups The BSI'S Reglonal and Affinity Groups are a key part of the BSI community and carry out much of the core activity of bringin8 our member5hlp together. The scientific discussions and networkin8 that take place at these meetings are Invaluable for the continued development of immunolo8y. The stren8ths of our 17 ReBiono1 Groups are to brin8 tO8ether immunologists within a local community boostin8 local research networks. The 12 Affinity Groups have all been created to focus meetin8S and discussions on speclflc areas of immunology and they continue to evolve as Immunology expands its reach and knowledge. Whlle the activltles of our Groups have been somewhat curtailed durSn8 the pandemic, thev approached thls year with renewed enthusiasm and ideas. In total, our Groups hosted nine in person conferences, two online conferences and three webSnars, covering a whole host of topics from 8 ce115 to tumour checkpoint blockade to avian immunology flow cytometry. These events played an Important part In our strate8V to develop our Re8lonal and Afflnlty Groups as communlty-based expert hubs. Our Groups also ran several other actNltles including in house seminar series, c8reers events and public Olrtreach Inltlatives. Our pro8ramme of events contlnued to be disrupted by COVID-19 rÈstriciions. Groups turned to online and hybrid events to keep members enga8ed and up to date with over 4,900 people attendlng events this year, over 1,000 more than last year. A full calendar of group events is planned for next year. 8SI Journals The BSI'5 origlnal eth05 Still Iles at the heart of our Society- to dlssemlnate research with the alm of promotin8 and advancing immunology to foster future innovatlon. Thls has been a busy and exclting year for our journals and one full of change. After a strate8lc revlew of our portfollo, the BSI decided to focus on developing journals that are fully owned by the Society to 8Sve us greater control over our publi5hlnB portfolio's future and to allow us to contlnue to support future generations of immunologlsts. This meant that our long- standing association with the Wiley-owned journal Immunology came to an end. However, we were delighted to cement our relatlonship wlth Oxford University Press, who became our new publishing partner for Clinical & Experlmentol Immunology. where it joined our Open Access journal ImmunotheropyAdvances, January 2022 alsQ Saw the exciting move of launchin8 our second fully Open Access journal, Discovery Immunology. Thls launch completes our highly respected famity of three journals serving the field of immunology, publishing high-quality research articles, review5, commentarie5 and short reports from researchers across the Elobe. Income generated from our journals provi(les major financial support for the Soclety's actlvities and we are hugely 8rateful to all our Editorial Board members for their ongoing commltment, and everyone who ha5 contributed to the continued success of our lournals, including authors, readers, reviewers and editors.

Cllnlul & Exp•rlm•iital IMMUNOLOGY Our establlshed translational research journal, Clinicul & Experirnenttil Immunology ICEII, continuès to go from 5tren8th to strength, and this year reached its highest-ever impact factor of 5.732 128% Increase from last yearl. We're Sncredlbly proud of this achievement and our thanks go to Edltor-in- Chief Leonle Taams and the lournavs edltorlal board fortheir hard work in bringlng about thls success. It's been a busy year for CEI all round, publishing a number of high impa¢t virtual issues and takln8 part in a number of collaboratlons includln8 hi8hli8htln8 primary research and revlew artlcles that complemented the sclentlflc programme of FOCIS 2022. mpact factor Cltatlons 3,592* 5.732 vg cltations per article 2021: Cltatlons are based on articles for prevlous two years. ADVANCES It's been another successful year for our first fully Open Access journal, Immunotheropy Adv(7nces. as It contlnues its journey to be a 810bal￿ recoBni5ed title that both Se￿e5 the immunotherapv community and exposes new developments in the field to a wide and diverse readershlp. Led by Editor-in-chief, Tim Elliott, Immunotherapy Advances publishes scientificalty rigorous research relating to manipulation5 of the immune system for the benefit of human and anlmal heatth in all dlsease areas. A hi8hlight this year has been the recrultment of an Ear￿ ca￿er Editorial Board who gain the opportunity to develop their skSlls as peer revlewers, learn more about the edltorlal process and contribute to the 8rowth and development of the journal. 125 cltatlons downloads

Discovery IMMUNOLOGY This year, the BSI launched Discovery Immunology, a fully Open Access journal whose broad scope focuses on new discoveries in cellular and molecular immunology. Led by Editor-in-chief Simon Milling and supported by 51x prestigious senior edltors and a growlng international Editorial Board from academia and industry* Discovery Immunology aims to publish hlgh-quality articles describing novel mechanisms controlling the immune response. After a successful launch. we are now focused on buildinB the reach and impact of the journal over the coming months. 'Our vision Is for Discovery Immunology to become an invaluable resource to the Immunolngy community, providing trusted new insights into the workings of the Immune system. Professor Slmon Mllllng, Edltor.In.Chlef, D15covery Immunology, Supportlng r•se•rth consortl• Under our updated strategy, a new facet of our work has been to support national and topic-specific research consortia efforts relevant to Immunology. By championing Investment in immunology and a 'team science, approach, we aim to use our skills to support cToss-sector collaboration efforts to drlve forwards immuno108y research faster and more effectively. This work has 8Ot off to a fa5t- paced start with the BSI provldlng a varlety of serylces to support two natlonal research detalled below. In addition, we are also continuing our sUPPQrt of the UK Coronavirus Immuno108y Consortium IUK-CICI to ensure the legacy of thls project and are currently supporting the SIREN ISARS-CoV-2 immunity and reinfection evaluation) study to deliver thelr participant involvement panel. CARINA Immunityfor life The CARINA ICAtalyst Reducing ImmuNe Agein81 Network is an Initiatfve funded by the Medical Research Council IMRCI and the Biotechnology and Biological Sciences Research Council IBBSRCI and supported by the BSI. The network was established to create a UK-wide, inclusive platfomi to enhance collaboration and foster knowledge exchange in the area of immune ageing. Involving over 70 researchers and ex￿rtS from a ran8e of disciplines and career levels, the network is identifying the priority areas for a better understandiFbg of immunity and ageing and how to address them through an interdisciplinary approath.

The Management Group, led by BSI President Professor Arne Akbar, provides important oversi8ht of the CARINA Network and directs network activtties by idenlifyinB novel research strategies. The BS1 has a leadin8 role in providing the project support that enables these activities. This includes the delivery of invotved project management to ensure important milestones are met, events 5UPPOrt to brin8 network members together for essential interactions, communication of the pro8ress of the network with key audiences through management of an online presence and embedding a patlent and public involvement component in the project. UKCovidVaccine Research Hub The National Core Studles INCSI programme was establlshed by the Government Office for Science In summer 2020 to ensure crltical questlons around COVID-19 could be answered quickly and effectNely. The Immunity programme, led by Professor Paul M05s and funded by UKRI, fund5 5tudles that deepen our understandln8 of immunity a8ainst COVID-19 by predicting indlvidual rlsk. preventin8 relnfectlon. understandin8 the vacclne responses by dIffe￿nt 8roups In more depth and preparlng for future pandemic challenges. As part of Natlonal Core Studles Immunlty INCSil work, the BSI has developed and runs the UK COVID Vaccine Research Hub Iwww.c vidvactineresearch.or hlghly successful webslte set up for the publlc, policymaker5 and researchers to provide the latest information on COVID-19 vaccine research being conducted in the UK. We also run the Patient and Public Involvement Panel for the consortia, ensurin8 that the expertlse and viewpolnts of publlc contributors are fed Into the various research studies that the initiative funds. Flnally, we support NCSI researchers in communlcatlng their work to policymakers, the medla and the publlc an acce551ble manner to maximise Its Impact and reach. KeeplnB members Infomied The BSI works har(1 to ensure good communlcation channels wfth our members, the wlder immunology communlty and the publ1¢ Informed about our actlvities and about development5 in immunology In the wlder world. This has been a particularly important part of our activltles thi5 year wkth the COVID.19 pandemic. The populartty of our webskte contlnues with 4.18 mllllon page views th15 year and 2.36 mllllon unique users. Our Infographics on COVID vècclnes continue to be the most viewed pages on the slte, wlth our compari50n of 'COVID-19 Imrnunity: Infettion compared with vacclnatlon, the m05t read page during the year. 4.18m page views 2.36m unique users

Bitesized Immunology, our online resource designed to form a comprehensive guide to the immune system tontlnues to be popular with flve of the top ten most read page5. Our social media channels continue to grow in importance as a way of engagin8 with our membership and the wider world at a more immediate level, to Interact wlth our supporters and spread the word about our work and the wonders of immunology. Across all channels, our social media posts were seen over 5.5 million times. Champlonlng careers The BSI provides several grant schemes to our members to support thelr work and thelr career development. These include a variety of activities- from covering the travel costs to conferences. to providing financial 5UPPOrt for carer5, SUPPOrt for public engagement Iniliatlves and those that promote diverslty and inclusion within imfflunolo8y. We are very proud of the ran8e of support we've provlded to members over the last 12 months. £225k grants awarded 339 members supported In 2021 we launched new Reglonal and Afflnty Group Travel Grants and Carers Grants- to support our members to attend In person meetin85 run by the BSI. 18 Communication and Engagement Grant were awarded to support publlc engagement prolectS run by our members 8 Carers. Grants were provided to 5UPPOrt attendance at BSI conferences Projects supported throu8h our Equallty. Dlverslty and Incluslon Actfvlty Grant include: Staff workshop to false awafeness of race-related Issues In the workplace Work experience scheme for year 11 and 12 students from backgrounds that are underrepresented in science Dlversity episodes of popular stience podcast Career Enhan¢lfi8 Gr•nts Supporting current and future generations of immunologists throughout their careers 15 a vital part of our mlsslon. This year, we launched a new grant scheme. our Career Enhancing Grants, to invest slgnifitant funds to provide flexible financial support to help or members reach their career goals. This scheme wa5 developed In response to feedback from our membership about the difficulties many were encountering in accessin8 this type of fvndin81 particularly in the wake of the COVID-19 pandemic.

£125k Career Enhancing Grants 36 members supported Generate pilot data Training courses Lab visits Mentorlng scheme Our highly successful mentorinB scheme brings together senior scientists with early career researchers to assist the next generation of immunologists with career development and pro8ression. The popularity of this scheme has flourished in recent years with 50 pairs matched up in this yearfs cycle. Over the last full cycle of the scheme. 90% reported the scheme met all or most of theirgi)als, with all participants saylng they were elther very or fairly well matched. Cllnlcal Immufiolozy trnlnln8 days We partner wlth the A550clation of Cllnlcal PathologSsts IACPI to run clinical Immunolo8y trainlng days almed at medlcal tralnees In Immunolo8y and allergyi and imrnunolo8y clinlcal sclentlsts preparing to sit the Royal College of Patholo8lsts In Immunology exams. By working together. the ACP and BSI ensure the contlnuous delivery of these hlghly valued training sesslons, helping to create a new generation of immunology-aware and informed clinicians and clinical 5cientlsts across the NHS to improve the care and treatment of patlents wlth Immune- mediated disease. The trainlng events themsefves are consistently ranked as excellent by attendees who value the targeted content. 'A really insplrin8 talk and overview of a potentially diflicult subject for clinicians. Very relevant and an area l often feel under confident with" Tralnln8 session attendee. Cel¢bratln8 excellence Our members use thelr skllls to work In many dlfferent sectors and drlve excellence in Immunology In a plethora of ways. It's the BSI'S honour to recognise the outStandin8 achievements of our members In all spheres of work that make up immunology. Honorary mqmbers Our honorary membershlp scheme [￿08n1ses individuals who hève made an outstandin8 contribution to immunology andlor to the Sotiety. At BSI Congress 2021, we were dell8hted to award Llfetlme Honorary Membership to slx members: Professor Danny Altmann Ilmperial College London) Professor Dame Sarah Gllbert IUniversr(y of Oxford) Professor Teresa Lambe OBE Iuniversity of Oxford) Professor Paul Moss OBE IUnNershy of Blrmlnghaml Professor Sir Andrew Pollard (University of Oxford) Professor Dame Flona Powrte Iuniversity of Oxford) io

BSI Global Impart and Innovation Award This year, we presented this special one-off award to all those involved in the design and development of the OxfordlAstraZeneca COVID-19 vaccine to recogni5e the huge achievement in developing this vaccine in such a short time perlod. This award recognises the contribution5 of the researchers in the lab and the clinics who designed and tested the vaccine, but also their support network5- legal, technical, admln, IT sUPPOrt, housekeepin& childminding- and the volunteers from the public who stepped forwards to take part in the clinical trials. At time of writingi more than 3 billlon doses of thls vac¢lne have been supplied to 183 countries around the world. It's estimated that this vaccine has saved 6.3 million lives in its first year of rollout, more than any other COVID-19 vacclne. This truly 15 an unprecedented achievement. Brlghi Sparks In Immunolo8y Our'Brlght Sparks, sesslons at BSI Congress aim to hlghllght exceptional work from PhD students and postdoctoral researchers. The standards of presentations this year were incredibly hl8h and we were pleased to award the followin8 winners. Postdoctoral category wlnners Flrst.. Dr Johanna Kabbert (Lund Univers1ty1- Hi8h microbiota reactivlty of human Intestinal 18A requlres somatic mutation5 Second: Dr Lucy Mcshane Iunlversity of Glasgowl- TAM receptor Axl loss accelerates atherosclerosis in mice Third: Dr Andrew McLean Ivniverslty of Oxfordl- Afveolar macropha8es coordinate early mlgration and differentiation of lung resldent memory B cells at infected sltes after Influenia rechallenge PhD category wlnners Flrst: Lucia Labeur lurman Ilmperlal College Londonl- An enrlched IL-2 environment In earty life limfc5 T folllcular helper cell development and protectlve immunity after resplratory virus infection Second.. Julle M Mazet Iunlversity of Oxfordl- Interferon-gamma rÈ8ulates antl-tumour response by restrirting cytotoxlc T cell potential in melanoma Third: Harry Horsnell IUnlver51ty College Londonl- Lymph node homeostasis and adaptatlon to Immune ¢hillen8e resolved by fibroblast network mechanics Immunolo￿ Teachlng Ex¢¢llen¢e Award This award recognises exceptional immunolo8y teaching in a hiBher education setting in the UK. Our winner this year was Dr Nicholas Barnes IUniver5ity of Manchester). He was particularly praised by the judges for his creative approach to pilot use of a web-based resource of patient case5, allowin8 students to formativety develop their Clinical and sclentific interpretative skSlls In an Interactive, safe environment and encouraging peer-discussion, Fearning and reflection. We plan to ramp up our efforts over the coming year to reco8nise excellence in immunology. Keep an eye on our website for more detallsl li

Catalysing change Partnershlps Working in partnershlp 15 a key pèrt of the British Society for Immunolo8y's strate8V to build the impact that we can delNer for immunology. We engage with like-minded organisations to collaborate on areas of common interest and perspective, with areas of interest ranging from autoimmunity, to cancer and vacclnes. By uslng our proflle, expertlse and reach, we can shine a118ht on the importance of crltical areas of immunology to attract new focus and funding. New fundlns for autolmmune research Throu8h our Connect Immune Research alliance, we partnered with The Lorna and Yuti Chernajovskv Blomedlcal Research Foundation, to award grants totalling f I million to ten 12-month pilot research projects to Identify the underlying causes of autoimmune diseases and Benerate new treatments. The studies examine a variety of areas inclL4din8 the genetics of autoimmunlty, potential new immunotherapy treatments and how different immune cell types are involved in the development of autoimmune condltlons. On completion, the most promislng projects wlll be invited to apply for follow-on fundlng to take thelr work forward. This initiative has shined a 5POtli8ht on the importance of this research area and provlded important new funding for this Important work. Our ultlmate alm Is to deliver signlflcant new Investment to confront the UK'S high prevalence of autolmmunity and develop new treatments ft>r multlple autolmmune conditlons, faster, The value of veterlnary vacclnes We partnered with the International Veterinary Vaccinology Network to publlsh a joint report on value of veterinary vaccinology research, which revlews the current state of the veterinary vaccinolo8y landscape and sets out the key recommendations to maintain the UK'S leadlng role in thls area. Supportlng efforts to Improve anlmal health is a key area of work for the 8SI. This report aims to help fijnders and policymakers better understand the vltal need to invest in animal vactine development to secure our food, economy and health for the fvture. The UK is a world leader In the field of veterinary vacclno108V* but lack of investment and further fundlng cuts threatens this excellence. food security and our ability to respond to global health challenges. The report lays out Immediate measures that can be taken to remove known barriers and ensure the numerous benefits of veterlnary vaccines are reaped by mlllions around the world. It Is only by Investlng in veterinary vaccine research, career development, collaborations and infrastructure that we can secure our future. EFIS Vacclne Task Force The BSI chairs Vaccine Task Force of the European Federation of Immunological Societies IEFISI to bring together immunolo8lSts from across Europe to pool resources and expertise to encourage the vaccine uptake by providing a strong, engaging, evidence-based and collective voice. Although the Task Force was established to tackle general vaccine uptake across Europe, due to the pandem￿, focus recently has been on increasing public confidence in COVID-19 vaccines across Europe. 12

Vaccine Task For Overthe last year, the Task Force has delwered several major project5 includin8 both policy reports provldlng the latest updates on the COVID-19 vaccines and public enga8ement work. For the latter, we have produced infographics for the public describin8 how vaccines work and why they are important, wlth a particular focu5 on COVID-19 vaccines. Languages covered so far include French. German, Greek, Irish, Lithuanian, Polish, Spanish and Ukrainian. Publlc engagement Our public engagemenl work over the last 12 months has focused prlmarity on COVID-19 and vaccSnes. We have used a wide varSety of methods and routes to en8aBe with different communitie5 to understand and answer their questions around COVID-19 vaccines.

VacclneCon¥e1$4tlon$

Empowering our members to engage with their famiW, frlends and communitiès to have meaningful conversations about vaccines, and in partlcular COVID.19 vacclnes, has been a core facet of our public en898ement work. These conversations from trusted individuals a￿ incredibly important in Strengthening publlc understandin8 and helplng people make Informed decision5 about vacclnation. yci to COVID-19 c￿￿11.7.j I>.vL ¥Ir￿1￿￿hDl%thth ryfylblD PV4MknI

We have continued to work wlth our members to help them have these conversations by providing range of resources to build communScation skllls and aid these conversation5, including sharing expert tlps on having constructive conversations about vaccination5. We have also continued to develop a range of engagement resources around COVID-19 vaccines, Includlng an updated version of our hlghly rated comprehensive "Gvide to COVID-19 vatcinations" and a number of info8raphics to explain key facets of our understanding of how vaccines work and how they Inc￿ase immunity to SARS-CoV-2. We have also continued to run ourvery popular Instagram Q&A sessions on COVIO-19 vaccines where members of the public can send In thelr questions for an immunology expert to answer. We also branched out into the arts sphere to encourage hands on learning through a new origami to create paper viruses and antibodies. C.OVID- 19 va('cinatii)n vircil vari¢int A4T[uNIAI Partnershlp for maxlmum Impart To build public trust and confldence in COVID-19 vacclnes, It's Important that we work wSth a varlety of organisations to increase our reach into different communitles. Throughout the pandemic, the BSI has partnered with a wide variety of or8anisations to make sure our inforrnation is 8ettin8 Out to those who need it. As well as our work with several local counclls (see below), we worked with the Cabinet Office to help find immunologists to speak at their'Keepin8 communities Safe, webinar5. tar8eted at an audience of community leaders nationwide. We also presented our own engagement work at this webinar Series, gaining lots of praise for our initiatives and leads for new collaborations with local authorities, charities and community groups. 14

We also partne￿d with NHS England, NHS Improvement andthe COVID Vaccine Connect and Research Hub on several prolects, including producing fla5hcards targeted at dlffeyent communities providing answer5 to key questions around COVID-19 vaccines and providing speakers for webinars on the topic aimed at healthcare professlonals. Throughout this work. we have not lost focu5 of the importance of continued en8a8ement around childhood vaccinations to encourage uptake and answer any questlons parents have. A major project we undertook this year on this wa5 to partner with the Department of Health and Social Care to create engaging short videos about the importance of chlldhood v8ccinations, featurin8 BS1 member5 answerlng common questions. These vide05 have been shared widely on social media channels, includin8 Twitter and Facebook, throu8hout the year, and have been viewed by manv thousands of people, helping to Increase awareness of the importance of these vital vaccinations. Effertlve conversatlons on COVID-19 v¥¢¢lfftes There has never been a more important time for Immunologists to engage with the public about vaccinations by11stenlng to and addresslng questlons and concerns. While the BSI and our members are idealty placed to be expert sources of knowledge in these dialo8ue5, working in partnership with organlsations that support local communlties is powerful In reachlng wider audlence5. Thls year, the BSI collaborated with the London Borough of Bexley and Bexley Voluntary Servlce5 Council, and later with Birmingham and Newcastle City Counclls, on programmes to train 'vaccine champlons, within local communlty groups to have effective tonversations wlth their peers about COVID-19 vaccine5. The programme was developed to traln people who hold soclal capltal In communitles by combiniTh8 our expertise in immunology with the expertise of the local area and people. Sessions were led prlmarily by BSI members. who were skllled communicators, With appearances from local community leaders. The sessions were u5er-led, meaning that particlpants shared key questSons they and thelr communltle5 had on COVID-19 vacclnes and the course content was adapted to address Ihe5e. Partlclpants were very positive about the trainlng, wlth l(KN of the community leaders feellng better informed, more knowledgeable and more confldent about havin8 effeCt￿e conversations about COVID-19 vacclnations. All community leaders reported having increased the number of people they talked to about COVID-19 vacclnes. Patlent and publ1¢ Involvoment Following our delivery of patient and public invofvement IPPII within the UK Coronavirus Immunology Consortium IUK-CICI, we partnered with them to publish a report to celebrate and showcase the posltlve impart of involving patients and the public in immunolo8y research. UK-CIC broljght tO8ether laborètory-based sclentbsts and clinicians with the experience and unique perspectives of patient and public contributor5. The PPI panel withln UK-CIC pn)vided a platform for regular two-way conversations with researchers to address key questions about the irnplicatiuns of the research as well as discussions about what was important to the publlc and patlent groups.

cic Thls report provides a gulde to our experlences of runnln8 that prolect and practlcal suggestlons of how to bridge the gap between baslc research and the Ilved experlences of patients and the publlc. By sharing learning and knowledge from UK-CIC and presenting the beneficial influence that PPI brlngs to sclence, we hope thls report acts as a guide on how to Include more PPI In Immunologv research. Pollty hlghll8hts The COVID-19 pandemlc has domlnated the BSI'S pollcy work over the past 12 months. The Soclety has continued to use our powerful voice to advocate for Immunologlcal science and health throughout thls tlme, enssjrlng the volce of Immunologlsts Is heard loud and clear In public debate5, and that policy-makers have access to the latest immunological thinking. with our dynamic approach, workln8 through our COVID-19 Ta5kforce, we have played a strong role in both ensurln8 the expert voice of immunologists Is represented In publlc debate and how the lessons learnt from the COVID-19 pandemlc response can be brought to wlder areas of health research, BSI COVllh19 Tasklorta Our expert taskforce has contlnued to Wofk hard thls year ensure that we can respond qulckly to the developments of the COVIO-19 pandemic as and when they arise. Our huge thanks to the taskforce members who have contrlbuted to thls work. Important hlghli8hts from thls work Include.. Publishing a FAQ Style brleflng paper on What we know about COVID-19 immunity, in winter 2021 aimed at MPS, members of the House of Lords and policymakers. The 8oal of thls was to provlde an easy-to-understand summary of this fast-movlng area of Scientific understandin8 to facilitate more evidence-based policymaking. At the request of Sir Patrick Vallance and the BEIS Vacclne Taskforce In wlnter 2021. our group prepared a list of what it believed to be the pressin8 immunological research questlons that affect publlc health in relation to the Omicron variant. Responded to several Parllamentary consultatlons including on the Idea of vaccine mandates for healthca￿ worker5, biological securlty strategy and UK sclence and technology strategv. Met with a number of hÈh proflle polbticians Includin8 Maggie Throup MP, Vaccines Minister, to di5CUss next generation Va￿l￿eS and learnin8 lessons of the COVID-19 vaceine deployment. 16

Westmlnster Hall debate The BSI has worked tirelessly to raise the ongoing imt)ortance of immunology research to the pandemic response. Following the efforts of our COVID-19 Taskforce, we worked closely Jim Shannon MP, DUP Spokesperson for Health, to Secure a Westminster Hall debate on 'lmmunoloBV Research and COVID-19'. We provided Mr Shannon with a briefing on important issues to raise in the debate and he was able to discuss most of these In presenting the case to ihe Minister, highlighting the important gains in knowle(Ige that immunology ￿searCh into COVID-19 has dellvered to bulld our understandin8 and deliver treatments and vaccines against the disease. This is an important step forward in our policy work and in rai5in8 the profile of immunology an(1 the BSI - debates such as these allow us to get 155ue5 Qn the radar of the relevant Mlnister, and elicit an officlal response. Enablers To delbver our ambltlous strateglc alms. we need to malntaln the BSI a5 a sector-leading or8anisation. We wlll do this by: Creatin8 a larger and more diverse engaged Membership Embedding quallty, diversity and inclusion In all our activitles Ensuring the Socletvs financial sustainablllty Enabler- membershlp Our membershlp is the foundation of our society. We are ambitious In what we want to deliver for immunolo8y and for our members. As the discipllne of Immunology grows and evofves, we alm to evolve too to ensure we engage with, support and are relevant to immunologists from across the spectrum of our discipline. As the largest professlonal immunology society In Europe and thlrd largest in the world, we aim to stand shoulder to shoulder with our members to support and champion the discipline of immunology to drive scientific discovery and make a positive impact on health. New supplxt and eniaiement opportunltles for members thls year One of our key aims to Increase membership engagement opportunities ha5 been well and truly met this year with a plethora of new o¢tivities and support to enable increased involvement and support for our members across the spertrum of BSI'S work. This included.. New Career Enhanclng Grant to provlde up to £5.(M)O of flexlble career funding Travel and carers 8rantS to support attendance at BSI Regional and Affinity Group conferences Additional opportunltles to get Involved in our public engagement programme on vacclnes Established Early Career Editorial Board5 for two of our journals, Clinical & Experimental Immunology and Immunotherapy Advances Both in person and onllne options to attend BSI Congress 17

New Diversity and Inclusion Framework launched with increased opportuntties to get Involved in our EDI activities Inueased investment in autoimmune research through our Connect Immune Research and Chernajovsky Foundatlon partnershlp Immunolo8y News Members in the UK have the opportunity to receive a printed copy of our quarterly membership magazlne, Immunology New5, Wlth online ac¢e55 around the world. Immunology News amplifies the volce of our membershlp and hi8hll8hts how we're supportin8 our members and representin8 immunolo8y on a wider Stage. Immunology Immunology Immur Immunology iilsrnv Iiverslly ogy f•1 all thyoug, h1Thur￿l0Q¥.. Over the last year edltlons featured the BSI 2021-2025 5trate8Vi the launch of our brand-new Open Access journal. Discovery Immunology, a recap of highli8ht5 from 8SO Con8ress 2021. The 2022 summer Issue was a speclal ed￿lon marklng the launch of our new Dlverslty & Incluslon framework where we lay out how we are going to work with our members and community to progress equlty, diverslty and incSuslon IEDI) work and 5howcaslng the èmazing EDI aCt￿ltIeS belng carrled outby our members. 18

Corporate members We would Ilke to thank our corporate members whose continuous support enables us to undertake our work 2@Scientific abbvie 10;, GENOMICS InvivoGen COULTER MABT. MEREK Mlltenyl Blots( nanoStrin9 STANDARD abcam IOYOOL8 • PEPROTECH. BIO+UID STEMCELL" 4 Q absoLute ? antibody l &k*.' Enat41ni Lryendvry DIKovw- CURIOX peptlde8&elephants 19

Enabler - Equality, dlveislty and inclusion The BSI wants diverslty and inclusion to be at the heart of the ethos of our community. We took a bi8 Step forward in our endeavours this year by publishln8 our new'Diversity and Inclusion Framework, This brin8S together all the BSI'S activities in this space to outline our commitment to how we are 80ing to work with our members and community to ramp up our equity, diversity and Incluslon work and respond to members. needs. Developed In consultation wlth our Board of Trustees and Forum members, our aim is to foster a culture wlthin Immunolo8y that ensures falr treatment and opportunity for all. By bulldlng on past and ongoin8 activitie5, this framework set out our lon8-term plan of action for diversity and incluslon at the BSI. Dlverslty & I nclusion Framework Enabler - Flnancial sustalnabllSty Income dl¥ersfficatlon To dellver our ambitTrous strategic plans, we need to malntsin the 8SI as a sector-leadln8 or8anisatlon, and one of the trucial enablers to do so is our finan¢lal sustalnabillty. Tradltlonally, the BSI has heavily relied on journal income to fund our charltable activities. With current changes wlthin the Scholar￿ publishing landscape, we need to secure new income stream5 which will provlde fundln8 for our artivitles and maintain the long-term financial security of the Socletvi while also allowlnB US to make a p051tlve contribution to the Immuno108y sector. The development of new Income streams is not a quick process as there is often a delay between investment and return requirlng the use of reserves. However, our strong reserve5 have been built up for exactty thls purpose to support us through this transition and thelr use Is now carefully planned. The key areas of our current work are discussed below. Wldenlni ouv lournals portlollo Changes to our publishing portfolio las dlscussed on page 51 In tandem wlth the global move towards Open Access publishing have seen the BSI significantly evolve our journals strategy. The overall aim behind this 15 for the Society to reduce our reliance on journal income, particularly that from traditional subscrlptlon Journals. while making sure we develop a modern publishing portfollo that meets the needs of our member5 and wider •mmunolo8y Community. The initial launch of our first Open Acce55 journal, ImmunotheropyAdvance5, Wa5 Swiftly followed this year by the debut of a new Open Access journal for the BSI. Discovery Immunology. Thls, partnered wrth our moves thls year to secure the future of Clinical & Experimental Immunology mean that the Society is now in stron8 Position to stabilise our future iciurnals income, whilst reducillg uur overall reliance on this. zo

Supporting imrnunolo8y rese•rch We have recentty expanded our artivlties to Include providing 5UPPOrt to wider immuno108y research efforts. Within the BSI staff, we have many specialist skills- such as communications, public engagement and involvement, 8overnance- that we can bring to large research con50rtia and networks to support their smooth rurbnin& effectiveness and impact. Prestl8ious projects we have worked with over the last 12 months include the UK Coronavirus Immunology Consortium, a nationally targeted effort to understand the immunology of SARS-CoV-2 and COVID-19, the SIREN ISARS-CoV-2 immunity and reinfection evaluation) study, National Core Studies Immunlty and the CARINA ICAtalyst Reducing ImmuNe ABeingl Network (see page 7 for more details). Thi5 type of funded project, through which we support the delivery of exlsting and new immunology con50rtia. is an important new 50urce of income for the organisation, and which is expected to contribute over IO% of our income next year. Fulure dlrectlon We have several addltlon81 new projects under development, whlch all fulfil our goals of makin8 a P05btlve Contribution to the immunology sector whllst also dSversifying the BSI'S income. Kev amongst these is to develop a trainln8 programme within the Soclety to meet the needs of both immunolo8iSts, helpinB them keep theii skills up to date and relevant, as well as non-immunolo8lsts who want to understand the ba51C5 to help them in thelr lobs. Structure, Governance and Management Charltable st1￿$ and admlnlstratlve detalls The Society was re81Stered as ? charity In 1966 Icharity number 10432551 and Incorporated In England and Wales as a companyi limbted by guarantee Icompany number 030059331. The Societws registered address is 9 Appold St￿et, London EC2A 2AP. It has no share capltal and the Ilabilhy of its members Is limlted to a sum not exceeding £1. The Society's 8overnin8 document is the Memorandum and Articles of Association, which was amended on 7 December 2016. It 15 a150 a registered charity in Scotland Ichèrity number SC0473671. Board of Trustees The Trustee5 are company directors for the purposes of the Companles Act and charlty Trustees for the purposes of the Charitles Att 2011. The current trustees, and any past Trustees who Se￿ed durin8 the year a￿ listed on pa8e 54. The Trustees are responslble for directin8 the SocieWs activities and for overseeing the management of the affairs of the Society, they delegate the day to day management of the or8anisation to the chief executive and the senior management team. The Board acts on advice and information from regular meetings with the chief executNe and the senior management team. As part of their induction process, Trustees spend some tlme wlth the chief executive and senior management team. They are provided a trustee resource pack containing the history of the Society and key information they require to fulfll their duties as Trustee, they are also offered training for new Trustees. 21

The success of the Society belongs in part to the large number of people who 8enerously volunteer their time to add their experience to our collection of committees. we thank you all. Flnance Sub Commlttee The Flnance Sub Committee en5ure5 the system of Internal control is satlsfactory to deliver regulatory compliance, flnancial problty, value for money, challen8e of financial plans, budgets and financial statements, oversight of the annual financial audlt, review of investment policy and performance, review of reserves policyi and CEO and staff remuneration. Nomlnations Commlttee The BSI'S Nominations Committee ha5 general oversight concernlng the structures and effectiveness of BSI Board of Trustees. commlttees, advisers and observers. It is also responsible for nomlnatlng individuals to represent the vlews of the BSI on extemal committees and to identify BSI members to nomlnate for external awards. Forum The Forum represents a dNerse mix of immunologlsts from dlfferent career stages, backgrounds and 8eo8raphic location5, Itls the Bsl's'thlnk tank, and the place where15sues and Ideas that are of importance to the Society and Its member are ralsed, dlscussed and developed. Congress Commlttee The Congress Commlttee is responslble for the plannlng and dellvery of the BS1'5 flagship event, BSI Congress, which takes place two out of every three year5. It reviews and approve5 the scientiflc programme for Congress. Cllnl¢al Commlttee The Cllnlcal Commlttee represents the wlder cllnlcal Immunology and allergy community and alms to enhance communication between sclentific and clinical immunology communltles. Group structure The Society hès one wholly owned subsldlary,. BSI Trading Limited is registered in the UK under company registratlon number 010201739. Its prlnclpal actlvlty Is to manage the corporate membershlp, sponsorshlp, exhibltlon and other tradlng activlties for the Society. This primarily compTi5es exhibition and sponsorship for the BSI Congres5. 22

Financial Performan This year the BSI entered our transition period folk)wing the changes to our publishin8 Portfolio. The Society moved to a net deflcit of £0.63m from net Income of £0.87m last year. The operating deficit before investments were better than budget, however losses on the value of our investment portfolio pushed the net deficit for the year hi8her. The BSI team rose to the challenge again this year posting total income slightly higher than 2021. however the Income mix changed slgniflcantlv. 2022 ££££££££££££££££££££££££££££ 2021 ££££££££££££££££££££££££££££ £2.21m Total lfflcomi £2.19m Publishlng income remalns the BSI'S largest source of Income, however thls fell by 41%, the BSI received SSX months income for Immunoloqy followin8 the return of the Ioufnal to Wiley, the Socievs p￿ViouS publisher. We welcomed Congress back in December 2021 wlth a record level of attendees. Thls together wlth a strong demand for exhibition space and sponsorship pushed the event to its highest ever income ft>r a Bsl-only Congress. The Society contlnued Its recent success obtainin8 fundln8 our work supportin8 the immunolo8V communit¢s work on COVID-19 project5. Total grants recewed were £0.25m an Increase of 66% from last year. A 8rant for É157k was received for creatlng a central co-ordination hub for COVID-19 immunology research investments and outcomes. Movin8 away from COVID the Society started a two-year Project to provlde admin 5UPPQrt to the new 'A8ein8 Across the Llfe Course, Interdlsclpllnary research network. Demand for the Soclety to provlde Patient and Public Invofvement IPPII In projects Is 8rowing followlng the succes5 of providing these serwices as part of our work in the above projects. Alihou8h relativety small thls Is an area for potentSal growlh. COVID-19 contlnued to have a significant Impact on the soclevs actlvitie5 durin8 the year; travel restrictions reduced our programme of physical events leading to reduced costs, a￿hoUgh the Society was dellghted to re-start our Conference travel grants In 2022. The launch of our new Career Enhancing Grants was successful with £125k of grants awarded in its first year. 37 Career enhancing grants awarded £125k Journal income £249k Grant Income received 12021.. £1491 40% BSI Trading Limited posted an annual profit of £0.34m12021- £0.12ml followlng the return of Congress. Thls was gifted to the society. 23

The Society is in a transition period following the reduction in journal income. The Society is focuslng on developing new income streams,. however. this will require investment from our reserves. Durin8 this period, we are forecasting cost5 to exceed income over the next few years until the new income streams start generating funds. Investment policy and p•rforrnancè The Society operates an investment poliry to provide income and generate capital BTOWth. The Society is a long-term Investor and the value of Its investments remalns slgniflcant above its orlglnal investment. It has been a challenging year lor investments. In the first half of the year our investment portfolio rose- however, the invasion of Ukraine triggere(l a sharp decline. During the spring the portfollo slowly regained some lost ground however it never made its way back to its highpoint at the end of December. The worsening cost of livlng crlsis produced falls In Investment values In June. Funds are invested wlth abrdn {formerly Aberdeen Standard Chartered) wlth a long-term objective to generate a capital return of 3% more than inflatlon over a three year rolllng perlod. As note above performance was challenging thls year resulting in net losse5 of £0.31m12021: £0.51m gain). The value of the portfolio fell by £0.31m12021.' rise of £0.51ml. Oft 30 June 2021 investments were valued at £4.26m12021: £4.45ml. The Finance Sub Committee 15 responslble for revlewln8 Investment perfornian￿ and pollcv. Reserves pollcv The BS1 operates a risk.based approach to reserves to ensure the 8SI holds the most approprlate level of reserves to cover potentlal risks and to fvnd Invest In new Income sources securing the BSI'S long term flnancial heatth. The risk register is reviewed annually wlth monetary values allocated to specific rlsks, restricted and designated funds. A provlsion for unknown risks (to 8lve cover for those risk5 of which the soclety is not yet aware) is calculated based as a percentage of the risk adjusted fund. The latest review resulted in total requlred allocated reserves of £3.71m12021., £2.75ml. On 30 June 2022 total reserves were £4.31m, includin8 free reseNes lunrestrlcted reserves less fixed assets) of £4.03m Biving an excess over the target of £0.32m12021'. E2.Ilml available for use by the Society to further its strateglc aims. Details of restrlrted fijnds tan be found In note 17 of the accounts with details of desi8nated funds in note 18. The calculation of the total required allocated reserves is performed on an annual basis. Pay pollcy The Societws pay policy aims to ensure that all employees are paid at least the market median for theSr role5 With the ability of high performers to move towards the upper quartlle. Salaries, including Key Management Personnel. are reviewed by the Flnance Sub Commlttee wlth recommendations for the annual pay rise proposed to the wider Board of Trustees for approval as part of the annual bud8etln8 process. The salary of the Chief Executive is reviewed annually by the Board of Trustees.

To increase transparency the Societqs is voluntarily reporting its gender pay gap. Caltulated in June 2022 the Society's mean gender pay gap is 32% (June 2021.. 26%), The pay gap indicates that while 72% of employees are women12021- 68%>, most men are in management roles. The Society employs more women In each of the quartile pay bands. The Society strongly supports equal pay. with indivlduals wlth the same respor$5ibilities beinB pald the same irrespective of gendei. Rlsk manasement Good rlsk management is fundamental to the continued work and sustainability of the Soclety. We identify and mange risks that could adversely Impact the achievement of our strategic purpose and determlne the calculated risks we need to take to succeed. The Society operates a formal framework for the management of risk, takin8 the view that risk can be positive lopportunityl or negative Ithreatl. The Society operates a rlsk reglster incorporatln8 strateglc, operational and compllance risks, which are informed by the Society's strate8lc objertives. performance. voice of our stakeholders, re8ulatory environment and analysls of the external envlronment. The Board delegates day-to￿aY responsibility for rlsk management to the Senlor Mana8ement Team, who are responsible for identifyin8 and evaluating risks to thelr areas and activltles Implementlng appropriate controls for ongoln8 mitl8ation and monitoring. The Flnanclal Sub Commlttee revlews the management of rlsk In detall at each meetlng and the Board reviews the Soclety's strategic and compllènce rlsks twlce a year. The major risks facing the soclety and the mitigation that we have put In place are as follow5: Rlsk RSsk response Fallure to dlverslfy our Income The Soclety Is proactively looking for new fundin8: Working with partners to develop important relationshlp5 With funders delNering increased grants and donations Implementlng a fundralslng strategy to develop new Income streams The Societyls heavily reliant on a slngle source of Income.. journals. Loss of slgnlflcant devaluatlon of investments The Society Review5 investment perfom)ance durln8 each Financlal Sub Committee meeting Communicates regularty with our investment managers, especially through tlmes of significant volatlllty A devaluation in the value of investments would result in a reduction of reserves available to use by the Society. Investments could be Impacted by sudden unforeseen global events 25

Fundra151ns statement Although the Society does not actNely fundralse from members, occasional donations are received. The Society applies best practice in the tone of its communications and the accuracy of Its data to minimise the pressures on supporters. The Society applie5 best practice to protect supporters, data, never sells or swaps it and ensures that communication preferences can be changed at any time. The Society commits to react to and investigate any complalnts received, to learn from them and improve its service. During the year, the Society received no complaints about its fundraising activlties. Future plans Durlng 2022-23 the Soclety wlll focus on: Conncctpd communlty Dellverlng a successful Con8re5s 2022 Delivering a new BSI awards ceremony Champlonlng careers Successfully Increase the careers support the BSI provldes to members Catalyslng change Contlnulng the BSI'S successful partnershlp work Expanding the 8SI's PPI activltles Enabler- membershlp Launchlng a refreshed membershlp offer Launching a new webslte Enabler- Equalltvj dlver51ty and Sncluslon Collecting benchmark EDI dota on BSI activities Enabler- Flnan¢ial sustalnablllty A smooth transltlon to long-term hybrld workln8 Launchlng new Income generatlng aCt￿ltIeS The Senior Management Team and the Trustees contlnue to assess the impact of COVID-19 on the Soclety. together wlth all other significant rlsks, in the ImmedSate, medlum and longer term. Trustees, responslbllltles The Trustees (who are also dlrertors of Brltlsh Society for Immunology for the purposes of company lawl are responsible for preparing the Trustee5' report and financial statements in accordance with appllcable law and United Kingdom Accounting Stondard5 Iunited Kingdom Generally Accepted Accountin8 Practice). 26

Company l?w requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Group and Society and of the income and expenditure of the Group and Society for that period. In preparing these financial statements, the Trustees are required to.. selert suitable accountlng policies and then apply them consistentty; obsenje the methods and princlples In accounting and Reportlng by Charitles- Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable to the United Kingdom and Republlc ol Ireland,. and make jud8ements and estimates that are reasonable and prudent: state whether applicable United Klngdom Accounting Standards have been followed. subject to any material departures dlsclosed and explained In the flnancial statements,. and prepare the flnancial statements on the 8oln8 concern basls unless St Is inapproprlate to presume the charlty will contlnue in operation. The Trustees are responsible for keeplng proper accountin8 records that disclose with reasonable accuracy at any time the flnancial posltlon of the Group and Society and enable them to ensure that the financial statements comply wilh the Companles Act 2006. They are also responsible tor safe8uarding the a55et5 of the Group and Society and hence for taking reasonable steps for the p￿VentIOn and detectlon of fraud and other Irre8ularitles. Each of Trustees confirm that: so far as the Tru5tee15 aware. there Is no relevant audlt Information of whlch the Group and Society's auditor is unaware- and the Trustee has taken all steps that he/she ought to have taken as a Trustee In order to make himself/herself aware of any relevant audit informatlon and to establish that the Group and Society'5 audltor is aware of that informatlon. This confirmation Is gfven and should be interpreted In accordance wlth the provlslons ot s418 of the Companies Act 2006. The Trustees are responslble for the maintenance and integrlty of corporate and financial information included on the Society'5 website. Legislation in the Unlted Kingdom 8overnlng the preparation and disseminatlon of financlal statements may differ Irom leglslatlon in other jurisdictions. Approved by the Trustees and si8ned on thelr behalf by: Arne Akbar BSI President Date.. 27

Independent Auditor's Report to the members and trustee5 of the British Society for Immunologv Oplnlon We have audlted the financial statements of the Brltlsh Sotletyfor Immuno108y foriheyèar ended 30 June 2022 which compiise the Group Statement of Flnanclal Activities. the Group and Parent Charitable Company Balance Sheets, the Group Cash Flow Statement and notes to the flnantial statements, includin8 3 Summary of significant accounting polltles. The financial reporting framework that has been applled in theif preparatlon Is applicable law and United Kingdom AccountinB Standards, includlng Flnancial Reportln8 Standard 102 The Financial Reportin85tandard applicabbe Inthe UKand Republicof Ireland Iunlted Kin8dom GenerallyAccepted Accountlng Practleel. In our oplnlon the financlal statements.. glve a true and falr view of the state of the group'5 and the parent charliable company's affair5 a5 at 30 June 2022 and of the group'5 In¢omln8 resoU￿e5 and appllcation of resources, including its income and expenditure, for the year then ended, have been properly prepared in accordance wlth Unlted Klngdom Generally Accepted AccountlnB Practlce.. and have been prepared in accordance wlth the Companies Act 2006, the Charltles and Trustee Investment (Scotlandl Act 2￿5 la5 amendedl, fe8ulatSons 6 and 8 of the Char4ties Ac¢ounts IS¢otlandl Re8ul8tlon$ 2006 las amèndedl and the Charltle$ Art ZOII. Bas15 for oplnlon We conducted our audlt In accordance wlth Internatlonal Standards on Audltln8 IUKI IISASIUKII and appllcable law. Our responsibllitles under those standards are further descrlbed In the Auditor's Responslbllltles for the audlt of the flnanclal statements sectlon of our report. We are independent of the charltable company in a¢¢ordan¢e wlth the ethlcal requirements that are relevant to our audit of the flnanclal statements In the UL includln8 the FRC'S Ethlcal Standard, and we have fvifilled our other eihi¢al re5ponsTrbilities in a¢¢ordance with these requirement5. We believe that the audit evidence we have obtalned Is sulficlent and approprSate to provbde a basi5 for our opinion. Conclus1ty￿ r•l•tih8 to 801•1 ¢onc•rn In audltlng the flnanclal statements. we have con¢luded that the trustees, use of the 8oln8 concern basls of a¢¢ountin8 In the preparatlon of the financlal stalerrent5 15 approprlate. Based on the work we have performed, we have not identllled any materlal uncertainties relatln8 to events or condltbons that. Individually or collectively. may cast 5ignlficant doubt on the charitable company's ability to continue as a 80ing concern for a perlod of at least twelve months from when the financlal statements are authori5ed for issue. Our responsibilities and the Tespon5ibilitie5 of the trustees wlth respect to 8oln8 concern are de5crlbed in the relevant settlons of thls report. Other Inlormatlon The other Informatlon comprlses the information in¢luded in the annual report, other than the financial statements and ourauditorfs report thereon.The trvstees are responsibleforthe other information. Ouropinion on the flnanclal statements does not tover the other infomiation and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance concluslon thereon. 28

In connection with our audit of the financial 5tatement5. our responslbility is to read the other information and, in (loing so, consider whether the other information is materially incon51Stent wlth the financial statements or our knowled8e obtained In the audltorotherwiseappear510 be materSally misstated. If we identify5uch material inconsistencie5 or apparent materlal misstatements, we are required to determine whether there is a material m155tatement in the financlal statements or a material misstaiement of the other information. If, base(l on the work we have performed. we conclude that there Is a materfal mlsststement of this other informatlon, we are quired to report that fact. We have nothin8 to report in thi5 re8ard. Oplnlons on other matt•rs presulbed by th• Companl•s Act 2006 In our oplnion, based on the work undertaken In the course of the audlt.. the Information given In the trustees. annual leport for the finan¢lal year for whlch the f)nanclal statements are prepared is conslstent wlth the financial 5tatements.' and the trustees, annual report have been prepared In accordance wlth appllcable legal requlrements. Matter5 on whkh w• ar• rqqulr•d to r•port by •xc•ptlpn In the Ilght of the knO￿edge and understandin8 of the Broup and parent tharitable company and Its envlronment obtalned In the course of the audlt. we have not identified malerlal misstatements In the trustees, annual report. We have nothln8 to report In respect of the followln8 matters where the Companles Act 2006, the Charltles Account5 Iscotlandl Regulatlons 2006 las amendedl and the Charltles Act 2011 requlre us to report to you If, In our oplnion.. the parent tharitable company has not kept adeouate and sufficient accountln8 records. or returns adequate lor our audlt have not been recelved from branches not visited by us,. or the parent charltable company's flnanclal statements are not In agreement wlth the a¢¢ountln8 records and returns., or ¢ertaln dlsdosures of trustees, remuneratlon speclfied by law are not made- or we have not recelved all the Informatlon and explartatlons we requlre for our audit; or the trustees were not entltled to prepare the flnanclal staiements In accordance wlth the small companles reglme and take advantage of the small companles exemptlon In preparlng the Trusiees, Annual Report and Irom preparlng a strate8ic report. R•spOn￿bIlItI•9 of trust••S As explalned more lully In the trustees. responsiblllties statement, the trustees (who are a150 the dire¢tors of the ¢harltable company for the purposes of company lawl ale responsible for the preparatlon of the flnancial Statements and for bein8 Satlsfied that they give a true and fair view. and forsuch Internal control 35 thelrustees determine 15 necessary to enable the preparatlon of flnanclal statements that are free from materlal mi5Staternen( whether due to fraud or error. In preparin8the financlal statements, the trustees are responslble for assessln8 the 8roup and parent charltable mpany's ablllty to continue a5 a going concern, disclosin8, as applicable, matters related to going concern and uslng the golng concern basis of accountinB unless the Irustee5 either intend to liquidate the group or parent ¢harltable company or to cease operations. or have no realistic alternative but to do so. 29

Audltorfs re5POnslbllltles lor the audlt of theflnandal statèments We have been appointed as audltor under Sectlon 44llllcl of the Charities and Trustee Investment Iscotlandl Act 2005. the Companies Act 2006 and Section ISI of ihe Charltles Act 2011 and report to you in accordance with regulations made under those Acts. Our objectlves are to obtaln reasonable assurance about whether the flnanclal statements as a whole are free from material misstatemenL whether due to fraud or erior, and to Issue an auditorfs report that includes our oplnlon. Reasonable assurance 15 a high level of assurance, but Is not a guarantee ihat an audlt ¢ondyued in accordance wSth ISAS IUKI wlll always detect a maierlal misstatement when It exists. Misststements can arise from fraud or error and are considered materlal If. Indlvldually or in aggregate. they could reasonably be expected to Influence the e¢onomlc dec151ons ol users taken on the basls of these flnanclal statements. Irregularltles. In¢ludinBfraud, are instances of non-compllance wlth laws and regulatlons. We deslBn procedure$ In Ilne wlth our responslbllltles. outllned abtsve, to detect material misstatements In respect of irreBularStles, includin8 fraud. The extent to whlch our procedures are capable of detertin8 irre8ularities, includin8 fraud is detalled below. Explanatlon ag towhit •xt•rt th• audltwas consld•r•d wMbl• of dèt•dlni Ir￿￿rIt1•$, In¢ludln8 fr•ud The oblectlves ol our audlt in respect of fraud, are,. to Identlfy and assess the rlsks of materbal mlsstatefflent of the flnan¢lal statements due to fraud,. to obtaln sufflclent approprlate audlt evldence regardlng the assessed rlsks of materlal mlsstatement due to fraud. throu8h desi8nin8 and implementln8 approprlate Tesponse5 to those assessed rlsks.. and to respond approprlately to instances of fraud or suspected fraud identified durlng the audit. However. the primary respon5ibllity lor the preventlon and detection of fraud rests Wlth both management and those charged with goveman¢e of the ¢haritable Company. Our approach was as follows.. We obtalned ah understandln8 of the le8al and regulalory requlrements appllcable to the tharltable company and consldered that the most slgnlficant are the Companles Act 2006, the Charltles and Trustee Investment Iscotlandl Act 2005 las amended), re8ulatlons 6 and 8 of the Charlties Accounts (Scotlandl Regulatlons 2006 las amendedl, the Charlties Art 2011. the Chaflty SORP, and UK flnan¢lal reportln8 standards as Issued by the Flnancial Reportln8 Councll We obtalned an understèndln8 of how the charStable company eomplles wlth these requlrements by dlstusslons wlth mana8emènt #nd those Charged with governance. We as5e55ed the rlsk of materlal mlsstatement of the flnanclal statements, Includln8 the r15k of material misstatement due io fraud and how it mighi occur, by holdlng discu551ons with management and those charged wlth governance. We Inqulred of management and those charged wlth governance as to any known Instsn¢es of non-¢ompllan¢e or suspected non-compllance wlth laws and regulatlons. Based on thls understandin& we deslgned speclfic approprlate audlt procedures to Identify instances of non- compliance with law5 and re8ulations. Thls included making enquiries of mana8ement and those charged with Bovernance and obtainin8 additional corroborative evidence as required. A5 part of an audit In a¢cordance with ISA5 IUKI we exercTrse profes5i0nal judgement and maintain professional scepticlsm throughout the audit. We also.. 30

Identify and assess the risks of materi31 misststement of the financial statements. whetherdueto fraud orerror, deslgn and perform audit procedures responsive to those risk5, ènd obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detectin8 a material mssstatement resultin8 from fraud is higher than for one resultlng from error, as fraud may involve collusion, forgery. intentional omission5, misrepresentations. or the overrSde of Internal Control. Obtain an understandlng of Intsrnal control relevant to the audit In order to desl8n audlt PrO￿dUreS that are appropriate In the clrcumstances, but not for ihe purposes of expres51ng an oplnion on the effeulveness of the group and parent charitable Company's internal control. Evaluatè the appropriateness ol accountin8 pollcles used and the rea50nableness of accountlng estlmates and related disclosures made by the trustees. Conclude on the appropriateness of the trustees, use of the 80in8 concern basis of actountln8 and, based on the audit evldence obialned. whether a material uncertalnty ex15ts related to events or conditlons that rnay tast 51gnlfl¢8nt doubt on the group and parent charltable company's ablllty to contlhue as a Bolng concern. If we conclude that a materlal un¢ertalnty exlsts, we are requlred to draw attentlon In our audltor's report to the related disclosure5 In the financial statement5 or, If such dls¢losure5 are inadequate, to modlfy our oplnlon. Our ¢on¢lusions are based on the audit evidence obtained up to the date of our audiiorfs report. However, future events or conditions may cause thegroup or parent charbtsble company to cease to continue 05 a 8oln8 concern. Evaluate the overall presentation. structufe and content of ihe financlal statements, includln8 the disclosures, and whether the financlal statements represent the underlyin8 transactions and events In a manner that achleves fair presentation. Obtaln 5uffl¢ient approprlate audbt evldencè regardlng the flnanclal Informatlon of the entltles or buslness activitles wlthln the 8roup to express an opinlon on the consolldated flnanclal statement5. We are responslble for the directlon, supervlslon and performance of the group audlt. We remaln solety responslble for our audlt report. We tommunlcate wlth those tharged wlth governance regardin& amon8 other matters. the planned scope and tlmlng of the audlt and si8nlflcant audlt flndlngs, Includin8 any significant delitiencies In internal control that we Identlfy durln8 our audlt. Us• ol our r•port Thls report Is made solelyto the charltable companls members, as a body, In attordance wlth Chapter 3 of Part 16 of the Companies Act 2(￿6,. and to the charity's trvstees, as a body, In accordance wilh Sectlon 4411ll¢l of the Charities and Trustee Investment 15¢otlandl Act 2005, and in reSp￿t of the consolldated finandal statements, In accordance with Chapter 3 of Part 8 of the Charitie5 Act 2011. Our audlt work ha5 been undertaken so that we mlght state to the charitable CoMpan￿S members and trustees th05e matter5 whlch we ale requlred to state to them in an auditorfs report and for no other purpose. To the fullest extent permitted bv law, we do not ac¢ept or assume responslbillty to bny party other than the charltable company, the charitable compan￿$ members. as a body, and the charlty's trustees, as a body for our audlt wtsrk, for this repori or for the oplnlon we have formed. J_A LLV Date 2 November 2022 Neil Finlay50n (Senlor Ststutory Auditor) for and on behalf of Moore Kingston Smith LLP, Statutory Auditor 9 Appold Street London EC2A 2AP Moore Kingston Smith LLP Is ellglble to art as auditor In terms of Sectlon 1212 of the Companies Act 2(Q6. 31

British Society for Immunology Consolidated Statement of Financial Activitie5 Year to 30 June 2022 Unrestricted funds General funds £'ooo Deslgnated funds E'(KJO Restrlcted funds E'OOO Total 2022 E'OOO Totèl 2021 £'ooo Note Incom•from: Grants and ¢￿natIOnS Inve5trnent5 Charitable actfvlties Membership P8rtnershlp work Congress Meetlngs and events Journals Totsl Income 274 280 151 190 113 151 160 91 512 59 913 1,892 160 136 512 59 913 2,211 145 78 45 108 1,552 2,186 319 Expendlture on: Ralsln8 funds Investment manaBèment fee5 Cost of ralsSn8 funds Charftable adlvltles Membershlp Congres5 Meetin8s and events Publicatlons and journals Pollcy and PublSc Affalr5 Nailonal Research support Partnershlp work Education and Careers Dlverslty and Inclu51on Put￿lC en8a8ement Communlcatlon5 Internailonal work Total eM￿ndIt￿le 41 30 41 30 13 2410 642 184 370 130 240 642 184 370 175 149 133 198 181 166 253 377 181 161 117 67 45 149 133 68 125 116 228 28 2,214 118 228 28 2,540 73 169 32 1,827 125 201 Nét Income l•xpondlturnl belgre ¥•ln5 IIos5esl on Investments and trnnsf•rs Net Éainslllossesl on investments Translefs between fvnds Net sncomelldelscitl 13221 11251 118 13291 359 12 13051 13051 507 90 15371 1901 12151 118 16341 Reconclllat5on ol fund5: Funds brought forward 3,933 986 25 4,944 4,078 Funds carried torward 771 143 4,944 There are no reco8nlsed galns ￿ losses otherthan those recognised above. All aetlvities are continuing. The notes on pages 35 to 53 fonn part of thtte financial statanents 31

British society for Immuno108y Balance Sheet 30June 2022 Grou 2022 Charl 2022 2021 2021 Flxed ass￿5 Tangible fixed assets Intangible assets Investments io li 12 49 93 4,259 4AOI 18 37 4,454 4,509 49 93 4.259 4AOI 18 37 4,454 Current assets Debtors Cash at bank and in hand 13 552 407 959 130 1,227 1,357 875 37 912 264 1,079 1,343 U•blllfj•$: Creditors.. amounts falllng due wlthin one ear N•t furr•nt a$wts 14 1,050 1911 922 435 1,003 1901 9081 436 Net assets io 4,944 Funds: Unrestricted funds General fund Desl nated lund 3.396 771 4.167 143 3,933 986 4,919 25 3.423 771 4.194 116 3,933 986 4.919 25 16 Re5trlcted ￿ndS 15 Total io 4,944 These financlal statements have been prepared In accordance wlth the provlslons appllcable to the small ¢ompanies reglme. These accounts were approved by the Board and authorlsed for Issue on 518ned on It5 behalf bv.. and were Ame Akbar, Presldent a- /g/./.~ Britlsh Society for Immunology. Company Umlted by Guarantee Company Re81stratlon Nurnber 03005933 IEn8lond and Wales) The notes on pa8es 35 to 53 form part of these financial statements 33

British Society fi)r Immunolo8V Consolidated Statement of Cash Flows 30 June 2022 2022 2021 £'ooo £'ooo Cash Ilows from opgratln8 actmtles,. Net cosh provided by operotlng uctlvlties 17651 203 Cash Ilows from Investln8 aCtI￿tI•l.. Income from Investments Purchase of tangible flxed assets Purchase of IntanBlble fixed assets Proceeds from the dlsposal of investments Purchase of Investments 151 113 1401 1571 521 599 16591 1831 15951 69 Nèt cash us•d In Inv•stlni actl¥ltl Ch•n4• In cash and cagh equlvalents In the year Cash and cash equlvalents at I july 2021 18481 1,485 270 1,215 Cash and cash equlvalent5 at 30 June 2022 637 1,485 N•t Incom• lor th• porlod las pgrih• stst•m•nt of flrtlnclal •ct*4Tltl•sl Adlustm•nt$ for: Depreciatlon char8e IGalnsl105ses on investments Investment Income Ilnciea5el decrease In debtors Increase Ideereasel In credltors Plet cash provlded by operatlnB a¢tbvltles 16341 866 305 15071 11131 11511 14221 129 1441 203 176S) Anatyslsof cash and cash •4ulval•nts Cash at bank and In hand 407 1,227 258 Cash held by investment manaBer5 Total cash and cash equivalont5 230 637 1,485 The notes on pages 32 to SO forni part of these financial statements

Note5 to the financlal statements Atcountlng pollcles The principle accountin8 pollcies adopted, judgements and kty sources of estlmatlon uncertalnty in the preparatlon of the Ilnancial statements are as follows.. Basts of prepr¥tlon The flnancial statements are prepared on a 8oln8 concern ba51s, under the historlcal tost tonventlon Modlfbed to Include the recognition of listed Investments measured at falr value, whlch15 consistent with the prior year. The financial statements have been prepared In accordance with the Statement of Recommended Practlce.. Accountlng and Reportlll8 by Charities I"The SORP"), the Financial Reporting Standard appllcable In the Unlted Kin8dom and Aepubllc of Ireland IFRS 1021 and the Charltles Act 2011. The 8rltlsh SLKiety for Immunology I"The Soclety") meets the definltion of a pybll¢ benefit entity under FRS 102. G￿er•I Inform•tlon The Society Is a charitable company In¢ofporated in England and Wales (company number030059331 and Is a charlty re8lstered in England and Wales Icharlty number 10432551 and reglstered as a ¢harilv In Scoiland Icharlty number SC0473671. The Soclety's re81stered address Is 9 Appold Street, London EC2A 2AP. Crltlc•l account1￿ lud8em•nts and kny sour¢•J of •$tlm•tlon un¢ert4lnty The preparation of financlal statements requlre5 the Sue of certaln crltlcal accountlng estlmate5. It a150 requires mana8ement to exerclse Its judgement In the pro¢ess of applylng the Group and Soclety accountlng policies. In the appli¢ation of the accountin8 pollcles. Trustees are requlred to make lud8ements. estlmates and as5umptlons about the carrying value of assets and Ilabillties that are not readlly apparent Irom other sources. The estlmates and underlylng assumptlons are based on hlstorl¢al experience and other factors that are consldered to be relevant. Artual results may dlffer from these estlmates. The estlmates and underlylnB assumptlons are reviewed on an ongoing basls. Revlsions to accountln8 èstlmates are recognised In the perlod In whlch the estlmate Is revlsed If the rev4sk+n only affects that period, or in the perlod of revision and future perlod5 If the revSslon affected current and future perlods. In the vlew of the Trustees, no assumptlons concernln8 the fvture or estimation uncertalnty affectSn8 assets or liabllltles at the balance sheet date are Ilkely to result in a material adjustment 10 thelr carrying omounts in the next financlal year. Golng concern The financial statements are prepared on a goln8 concern basls whlch assumes the Soclety and Group wlll contlnue to meet its liabilitie5 as they fall due for a period of at least twelve months from the date of the approval of these auounts. The Trustees are monltoring the impact of Covid-19 on the Soeietv and Group. ThF5 includes regular review of the pandemic's impact on our member5 and our ability to deliver our activitie5 a flexible approach to our annual plan, rolling forecasts and In depth review of ¢tual financlal results. The immunology community Is at the heart of work on Covid-19 leadlng to the Society being busier than ever and attracting new fundin8 to support this work. This together with the hoSdin8 of 518nlficant levels of cash and investments result in the Trustees considering the Society and the Group to be a goln8 concern.

Notes to the financial statements Inwme All income is re¢o8nised once the Society and Group has entitlement to income. It Is probable that income will be received and the amount of income receivable can be measured reliably. Income of the Society is. whèrè applltable. Included net of Value Added Tax IVATI and Is allocated to the perkld to whlch It relate5, carryln8 forward that part of the income relatlng to future accountlng perlods. Investment Income Is reco8nlsed on a receivables basis and whèn the amount can be measured rèliablv. Expendlture Liabllities are reco8nlsed as soon as there Is a legal or constructlve obllgation commltting the 5oclety and Group to that expendI￿re. It Is probable that settlement will bè rèquired and the amount of obllgatlon (an be measured rellabty. Expendlture Is reco8nised on an accruals ba51s a5 a Ilablllty is Incurred, Inclu51ve of VAT, whlch cannot be Tecovefed. Expendlture Is allocated to a partlcular actlwty where the ¢ost fèlates dirertly to that aCtI￿ty. The Cost of overall directi¢*n and administration of each actlvlty, known as support Costs" and comprisln8 the salary and overhead costs of the central functlon Is apportloned based on staff tlme attrlbutable to Support costs also Include governance costs. whlch comprlse or8anlsatlonal admlnlstratlon and compllan¢e with ¢onstltutional and Statutory requirement5. The allocatlon of 5UPPOrt and 8overnan¢e costs Is anaty5ed in notes 7 and 8. Employ•4 b•noffts Short-term benefits Including hollday pay are recognlsed as an expense In the perlod In whlch the service15 received. TermSnatlon payments are accounted for on an accruals bas15 and In Ilne wlth FRS 102. The So¢lety contrlbutes to a Group penslon xheme, the assets ol whlch are admlnlsteied by Royal London Plc. They are deflned contrlbutlon schemes. All contrlbuted costs a￿ accounted for on the basls of char8lnB the cost of provldln8 penslon5 over the period when the Sts¢iety and Group benellts from the employees, servbce. The Soclety and Group has no further Ilabllity under the stheme. Le?￿nI and hlr• pur¢h•M ¢ommltm•nts Rentals pald under operatlng leases are charged to the Sncome and expendltvre account on a stralght Ilne bas15 over the lease term. The 5oclety holds no assets under finance leases or hlre purchase contTactS. Tan8lble fixed assets Tangible assets are stated at C05t less accumulated depreclatlon. C05t Includes the orlglnal Purchase pr1￿, costs dirertly attributable to brlngln8 the asset to its worklng condltlon for Its Intended use, dlsmantlin8 and restoration costs. The minimum threshold 15 £1,000. Depreciated is provided at 33% in order to wrSte off each asset over its es14mated useful life. Intan8lbk fixed assèts Intan8ible assets are stated at cost less accumulated amortisation. C05t includes the original purchase pr1￿, costs directly attributable to brln8Sn8 the asset to Its working condition for its intended use, dlsmantling and restoratlon costs. The mlnlmum threshold Is £l,OW. Amorti5atlon is provided at 20% In order to write off each asset over Its estlmated useful Ilfe. Assets In the course of constructlon are not mortised.

Notes to the financial statements Investments Investments are a form of basi¢ fihan¢ial instrument and are Inltlally shown in the financial statements at fair value. Movements in the fair value of investments are shown as net gains and losses in the Statement of Flnandal ACtI￿tIeS. Profits and losses on the realisation of investments are shown as reallsed galns and losses In the Statement of Financlal Aciiwties. Net gains and losse5 on investments are ¢al¢ulated between sales proceed5 and their openlng c3rrylnB values or thelr purchase price if acquired subsequent to the first day of the Ilnanclal year. Unrealised galns and losses are calculated as the dlfference between the falr value at the year end and their carrylng value. Rea115ed and unreallsed Investment galns and losses are combined in the Statement of Flnanclal Actlvlties. The Investment In the subsldiary undertaklng Is Included at cost wlth provlslon belng made for any permanent dlmlnutlon in value. Hn•nclal Instruments 11 Flnanclal assets Baslc financlal assets, Includln8 trade and other re¢elvables. cash and bank balances, are InitSallv re¢ognSsed at transactlon value and subsequently measured at amort15ed c05t. Other flnanclal assets. includin8 investments, are ln1tlal￿ measured at folr value. Flnanclal assets are dereco8nlsed when.. al the contractual rl8hts to the cash flows of the asset explre or are settled, or bl substantlally all the rlsks and reward5 of the owneishlp of the asset are transferred to another party or cl despite havln8 retalned some $18nifi¢ant rlsks and rewards of ownershlp, control of the asset has been transferred to another party who has the practical abillty to unllaterallv sell the asset to an unrelated thlrd party wlthout Imposln8 addltlonal restrl¢tlons. Cash at bank and cash In hand includes cash and short-term hlghly Ilquld Investments wlth a short maturlty of three months or less. 111 Flnanclal Ilabllltle5 Basic financlal Ilabllities, Includlng tfade and other payables, are initlally recoBlli5ed at transa¢ti prtce. Trade payables are obllgatlons io pay forgoods or servlces that have been acquired in the ordlnary course of buslness from suppller5. Accounts payable are ¢lasslfied as current Ilabllltle5 If payment 15 due wlthln one year or less. If not, they are presented as n0n-Cur￿nt liabillties. Flnanclal Ilabillties held at arnortised cost ¢ompilse all creditors except Social 5ecurlty and other taxes ond provlslons. Pro¥lslons Provisions are reco8nlsed where the Sodety has a present le8è1 or ¢onstru¢tlve obligatlon resultlng from a past event that will probably result In the transfer of funds to a thlrd party and the amount due to Settle the obligatlon can be measured or e5timat*d reliably. Provisions are measured at the present value or the expenditures expected to be required to Settle the oblisation. 37

Notes to the financial statements Fund accountlng un￿strICted funds are those funds available to the Society and Group for general purpose5. They Include funds designated by the Trustees for partlcular purposes where thelr use remalns at the discretlon of thè Trustees. 11 15 the policy of the Trustee5 to retain in unrestrlcted fvrtds, amounts whlth in thelr judgement, can help to mltl8ate the short-teTm effects of income volatllity- and retain as long-term Investment lunds to generate sufficient Income to meet current and future operatlonal artivlties ¢f the Society. Restrlcted funds are those funds avallable to the Soclety and Group restdcted to a speclflc purpose or are sublett to particular donor Imposed condltlon$. Further Informatlon Is avallable In the reserve$ Section of the Trustees, report. 38

Notes to the financial statements Income from grant5 and donatlons 2022 Totsl funds 2021 Total funds £'ooo Unr•strlrted lunds Restrlcted funds £'LTh)O £'cwl Grants Donatlons Total 249 25 274 249 31 280 L49 41 190 In¢om• from Inve5tment5 •nd Interest 2022 Total 2021 Total £￿00 Unrestrlrted Restrlcted £.￿0 Llsted Investments Investment Income Bank de oslt interest Total 151 151 113 151 151 113 Incom• from charltable actlvltles Unrestrltt•d funds Rastrlrted funds 2022 Total lunds 2021 Total tund5 £'ryJo Member subscriptSons Corporates and partnershlp Income Con8re5S Meetln8s and events journals Total 160 91 512 59 913 1,735 160 136 512 59 913 1.780 145 78 45 108 1.552 1,883 45 39

Note5 to the financial statement5 Totsl expendlture 2022 UnrestrlLted funds £'ooo Designated lunds £'ooo Restritt*d lunds Totsl £'ODO Roisingfvnds Investment managemert lee5 FundraisiDg Charitable Expendlture.. Membership Congress Other meetin8s antl events Publlcatlons and journals Polity and Public Affalrs NatSon81 Research support PartnershSp work Educaikjn and Careers Dlver51ty and Incluslon Publlc enga&ement Communkatlons IntÈrTratlonal Work Total 41 30 41 30 240 642 184 370 130 240 642 184 370 175 149 133 198 45 149 133 68 125 116 228 28 2,114 118 228 28 1.540 125 2rii Al+ocatlon of supwrt costs to charftable 8ctlvttles.' Olrect costs £'ooo Support tosts £'ooo 2022 Total £'ooo Rolslnqfvnds Investment rnana8ement fees Cost of ralslng funds Charltoble ortlvttles Membershlp Congress Other medin8s and events Publication5 and lournals Pollry and Public Affalr5 Natlonal Research support Partnership work Education and C4reer5 Oiver5ity and inclu51on PublK engagement CoMmunicat￿nS International Work Total 41 30 41 30 169 596 163 309 125 149 112 177 71 240 642 184 370 175 149 133 198 21 61 so 21 21 97 142 28 2,142 21 86 118 228 28 2,540 398

Notes to the financial statements 5 Total expenditure Icontlnuedl Support costs are as follows.. 2022 2021 £'ooo £,0￿) stsft costs 198 185 Premises costs 71 Depreclatlon IT and electronlc communlcatlons costs 67 65 Other 81 50 Aecrultment fees fjovemance costs (note 61 Total 13 12 398 Support costs have been allocated based on tlme spent by departments supportln8 the varlous actlvbtle5, Unrestrlcted funds £,￿0 Desl8nated funds Restrlrted funds 2021 £'ooo Rolslnqfunds Investment management fees Fundraisin8 Chorltoble Expendlture.. Member5hlp Congress Other meetln85 and events Publicatlons and journals Pollcy and public affalrs National Research support Partnershlp work Educatlon and careers 36 36 13 13 181 181 166 166 253 253 377 377 176 181 161 161 87 31 118 62 67 Public èn8agement Communlcatlons 73 73 146 23 169 International work 32 32 Total 1.602 223 1,827 41

Notes to the flnan¢ial statements Go¥ernance costs 2022 2021 Audltorfs remuneratlon- audit Audltor's remuneration- other 12 li Total 13 12 Net Income before Baln$110ssesl on Investments Thls Is stated after charglng.. 2022 2021 £'ooo Staff costs (note 91 Operatln8 lease rental Depreclatlon Audltorfs remuneratlon. audlt Audltorfs remuneratlon other 1.182 1,103 90 12 li

Notes to the finantial statements Staff c05t5 Stsff c05t5 durin¢ theyear were as follows.. 2022 £'ooo 2021 £'uoo Wa8es and salarles 5oclal securlty costs Pen51on tosts Total 1,009 118 55 1.182 962 91 44 1.103 The average monthly number of employees durlng the year wa5 a5 follow5- 2022 2021 Olrect charRable artSvhtles Admln15tratloTr of the charlt 16 17 19 20 Number of ernployees whose annualbsed ernoluments fall wlthln foll¢)wlng rawes for the year.. 2022 2021 £60.001- £70,0 £70,001- £80,000 £80,001- £90.0(KS £130,001- EJ40,000 £140,001- £150,000 Pensbn contrlbutlons lor these Èmployees were É21,84812021- £19,6251. The number tsf staff for whorn retl¥ement benef￿$ are accrulng under rnoney purchase Fonslon schemes amounted to 19 12021- 211. The Sccletyconslder$ Its key rnanaBernent personnel comprlse theTrustees and the 5enlor Ma1M8eTh￿￿t Team ISMTI. The Trustee5 provlde thelr tlme free of charge. The total remuneraiion, empl¢)yer's natlofial In5uranc• Contrlbuiions, beneflts and penslons pald to the SMT was E516.09512021- £484,192>. The relevant staff co$ts have been Included In thecosts of charltable actlvities.The gender spllt In the soclety workForte Is 67% female 33% male12021.. 74%temale 26% malt). All roles are evaluated aThd pald In attordance wlth externol benchmarklng Irrespectlve of 8ender. 9 Trustees, remuneratien No trustees recelved any remuneratlon for h15 or her 5eThices durfng the year12021- nonel. Dudngthe yearexpense5 totallinE E4.78312021- £nill were ¥eimbursetl to 7 tru5tees12021-nlll. In addltlon E5,483 was paid for travel and accommodatlon costs on behatr of trustees12021.. £nlll. One trustee received a £250 B51 Congress 2021 Edueation and Publlc poster prlze for best presentstlon and Communlcatlng Imrnuno108V grant of £l.OtX) for hls prolect entitled'SuperbuBS'.12021- One trustee ￿CeIved a prlze of £25 for best p￿sentatIOn as voted b¥ attendees of a reglonal meetlngl.

Notes to the financial statements 10 Tanglble assets of the fjroup and ¢harlty Web51te Computer equlpmènt Total Cost or v8luatbon At l Juty 2021 Additlon5 Dlspo$415 At 30June 2022 29 29 38 38 30 O•prnclatlon At l July 2021 Charge for the year Ellmlnated on d55posal At 30 June 2022 li li 20 20 Net book vglue Af 30 June 2022 38 io 49 At I july 2021 18 l8 11 Int•nilble assets of Group and ch4rlty Ir software Total £Tho C05t orv¥lwtSon At l Juty 2021 Additions 37 57 37 57 D15posals At 30June 2022 93 93 Depre£latlon At I july 2021 Charge for the year Elirnlnated on diSP05BI At 30 June 2022 Net book value At 30 June 2022 93 93 At l July 2021 37 37 ConstnKtlon of a new CRM system started in the year and 15 expetted to be completed next year.

Notes to the financial statements 12 Investments Group 2022 Charlty 2022 2021 2021 £'ooo £'oc £wJo £'ooo Mark•t value •t l Juty 2021 Dlsposals proceed5 Reallsed 8alns/llossesl Addltions at C05t 4,196 15211 1571 659 3.693 15991 46 4,196 15211 1571 659 3,693 15991 46 595 595 Unrealised galns Mark•t value •t 30Jun• 2022 12481 4,029 230 461 12481 4,028 230 461 4,196 258 4.196 258 Cash helLI wlth Investment managers Total Investments 4,259 4,454 4,259 4,454 Tolal Group Investsnents In¢ludes £IIXJ Investment In sub51dlary. Group Charlty At 30 June 2022 the Ilsted Investments mprlsed the followinB- 2022 2021 2022 2021 £'ooo £'ocK) £'ooo UK equltles Overseas equltles Investment Instruments 1,244 2,270 515 1.157 1.944 1,353 4,454 1,244 1270 515 1,157 1,944 1.353 4,454 Totsl 4￿29 4,029 Hlstorlcal cost of Ilsted Investments 3,317 3,470 3,317 3.470 At 30 June 2022 no holdlngs held represents more than 5% of the total market value of the portlollo of Ilsted Investments. 45

Notes to the Ilnantlal ￿ateMentS 11 Inve5tmen¢s Iront￿Ue￿j th￿5¢m¢￿tIn$￿&Swl•Yu￿dertv￿Q The Soclety own5 100% oltheordlnèry Isswd shore copknl of BSI Tfadlng ￿mited, a compory reglstered in England and Wales (Company rbumber010217391. Its rewstered addres515 9 Appold Street Londgn ECZA 2AP. The prlnclpal actlvttyol the company Is the mana8emeni of corpoi¥te membershlpi sponsorshlp. exhlblvon and other tradln8actl%Atlesforthe Soclety. A sumrnary of the re5ths of the subsldlary Isshown bek)w- 2022 £'ouo Z021 £'ooo Turnover 354 133 eratln osts eratln ront 354 133 AdMI￿stratIon costs Profltllossl foi the flnanclal perfod 335 123 Dlstrlbutlon to parent charlty 13351 Retained In sybsjdiarv The comwny'sassets ond118bllhles ot 30June 2022 were ￿ follows.. Assets 388 148 1388 11481 14et asset$ 13 Dqbt¢rs Group 2012 Ch•rlty 2022 2021 zoii £'ooo £'ooo £'ooo Trade debtors 358 14 341 14 Prepayment5 and actrued income Amount owed by subsldlary undert)kin8 VAT reeèsvable 194 92 194 92 134 24 24 Total S52 130 875 264

Notes to the financial statements 14 Crèdltors Group 2022 Charlty 2022 2021 2021 £'ooo £(￿0 £'ooo Trade credltors 355 60 345 60 Other taxes and so¢lal securlty costs VAT payable other rredltors Accruals and deferred Income 39 49 39 49 124 13 124 13 527 800 490 786 Total 1.050 922 1,003 Included wlthln the above Is deferred Income as set out below.. GfOUP Charlty 2022 2022 £YJ Deferred Income brou8ht forward at l Julv Addltlonal Income deferred durlng the year Brought forward funds releaged In the year Deferred Income tarried forward at 30 June 800 786 459 422 18001 459 17861 422 Deferred Income comprlses advance payments of journal royaltles and membershlps fee$. 47

Notes to the financial statements 15 Restricted fun(Js At l July 2021 At 30 lune 2022 Income Expendlture MeetSnE funds 34 34 Autolmmunitv UK-CIC io 15 12 53 1291 1241 Vacclne tsskforce 25 8lteSlzed Immunolo UK Covld Va¢clnes Rese8r£h 157 1961 1241 61 AgelTh8 and ImmuThlty 51REN 24 io 1mmun08er￿dtY project 35 27 Total 25 J19 143 Meetln8 funds Donation5 to the Society by Indlviduals to promote certaln immunological issues. Autolmmunlty A 8rant from the Lorna and Yutl Chernalovsky Blomedlcal Research Foundètlon for admlnistratlve support for ihe devdopment and mana8ement of the autolmmune reseorch Inltlatlve. UK-CIC A 8rant for the BSI support provlded to the UK Cofon•¥lrus Immunologyconsortlum IUK-CICI to understand the Immunology ol SARS-CoV-2 and COVID-19. Vacclne tzsklortÈ Fundin¢ from the European Federatlon of ImmurK)loglcal Socletle5 IEFISI for the EFISVacclne Taskforce work led bv the BSI. 81teSlzed Immunology Oonations re¢elved to upd•tE the 851,5 onllne resource, 8lteSlzed lrnmunolo8V* whlch p¥ovldes a comprehen51Ye 8uide to the immune sy$tEm e5pe¢ially 5uitsble for blomedlcal under8raduote5 and those Trew to Immurbo108V. UK Covid Vactines Research Hub Central cO￿rdInatIon hub ler cov1￿19 Immunology research Invesiments and outcomes funded by UKRI via the Nèiional Core 5tudles pro8ramme. AgeinB ard Immunity The CARINA Icatalyst Reducing ImmUNe￿elnsl Network is a new Collabotati￿ networktor researchersworkln8 On the Immune system throu8hout the life course. The 851 has a kndlng role In Suppor￿n$the network through prO￿$10n of project managemenl eveTht5 SUPPOrt, communlcatlons empertlse ènd patient And publlc Involvement 48

Notes to the financial statements 15 Restrlct•d fund5 Icontlnuedl SIREN Recrultrnent. faclllt•llon and rewrtlTrB of flndin8s from Patlent and Partlclpant Irwolvement workshops for the SIREN prolectfunded bythe UK Heahh Securlty Alency. Imrnunogènlclty prolect Immunogenlclty measure5 In ¥è¢¢lne development and dec151on makln8 proyamme funded by Merck Sharp & Dohmè IUKI Llmited. Atlju 2020 At 30 June 2021 £'ooo Income EMpendlturÈ £'coo MeetlnKfurKI$ Cèlebrate va¢clnes Covid-19 Connect on eoron•v4rus Autoimmunlty UK-CIC Voc(Ine t•skforie 8￿e511ed Immundoav 34 io 13 iioi 15 137 26 io 1241 11611 1261 Total 57 191 IZ231 25 16 0esl8nated funds At l July 2021 00518nat In year utllbsed I f•lèas•d At 30 Jun• 2022 Lon¢term sl￿￿￿nI1￿1fjty CRM prolect Career development pro8ramme 248 23 500 113 625 11251 Total IZ151 771 Long term sustalnablllty The lon8 term sust)Inablllty fund pro￿dEs rtsowces for In¥estln8 In the ftnèn¢ial 3ustslnablllty of the charlty over the neKtfve Years. CRM prole¢t The CRM project fund provld*s resourtes to develop and implernent o new CRM system tO8etherwhh on upgradeto the BS1 webslte Career development WO8ramme The Career development programrne wlll fund a sIgn￿l¢ant expansion in thecareers support the BSI offer5 toour member& Thls IrKludestwo main ￿reaMS.. our career-enablin8 act[￿leS and our career-enhanc1ngactl￿tles. 49

Notes to the financial statements 17 Analysis ol nets assets between funds 2022 Unièstridèd funds Dèsi8naied funds £'ooo Restricted fund5 Total funds Group Tan8ible fixed a$5ets Intangible assets Investmeftts Current assets Current liabilitles Total Fund5 49 93 4,259 45 1.050 49 93 4,259 959 11,osoi 771 143 771 143 2022 Unrestrlfted funds Oesl8nated funds £'ooo Restrlcted funds Total funds Charlty É'tsjo Tanglble flxed assets Intanglble assels Investments Current assets Current Ilabllltles Total Funds 49 93 4,2S9 25 1,003 3.423 49 93 4,259 912 1.003 4,310 771 116 771 116 The total unreallsed 8alns Ilosse51 as at 30 lune 2022 constltutes movements on revaluatlon and are as follows.. 2022 £'(Tr)o 2021 £'ooo Unr•allsod 8alns Iloss•sl Includ•d ab¢¥•.' On Investments Total unrealls•d 8aln$ IIDM•g1 at 30Jun• 734 734 983 983 R•condll•tlon of mowm•nts In unreallsed 8alns (lo￿$ Unrealised galns at l Juty Less.. In respect to dlsposals In the year S22 983 522 Add.. net galns Ilossesl art51ng on revaluatlon ar15in8 in the year 12481 461 Total unrealised ains (losses at 30June 734

Notes to the financial statements 17 knaty$15 of nets a$50ts between fund5 Icontlnuedl 2021 Unrestricted funds Desl8nated funds Restricted funds £'ooo Total funds Group £.￿0 Tanglble fixed asset5 Intanglble flxed asset5 Investments Current assets 18 37 4,454 346 19221 3,933 18 37 4,454 1.357 9221 4,944 9B6 25 Totsl Funds 25 2021 Unr*strlcted funds £'ooo Designated fund5 £'OLXJ Restrltted funds Total fund5 Charlty Tan8lble fixed assets Intan8ible fixed assets Investments Current a55ets 18 37 4,454 332 19081 3,933 18 37 4,454 1,343 9081 986 25 Total Funds 986 25 18 Share capltal The company Is Ilmlted by 8uarantee and therefore ha5 no share ¢apltal. Each member's liablllty Is Ilmlted to £1. 19 Related party transactlons Matthlas Eberl re￿iVed a £250 BSI Congress 2021 Educatlon and PublSc poster prize and a Communlcatln8 Immuno108V 8rant of £1,0￿. Calum Baln bs a member of the Edltorlal Board of Immunolwy, no payments were made In relatlon to thls. There were no other related party transactlons that requlred dlsclosure in the current fflnanclal perlod12021.' none), 51

Notes to the financial statements 20 Comparatlve consolldat•d statement of flnanclal actlvltles Unre5tncted fund5 General Deslgnated Rest￿Cted 2011 Inrom• frorn.. Donlons 188 L9Q ila InvEStments haritab￿¥C￿¥l￿e5 Membershlp Portnershlp wor ¢on8res5 MeefjnÉsande¥entS 145 145 78 71 108 Totsl knrom• 1.99S 191 2.186 Rolslngfvnds Investrnentmanayrnént Feès C05t of ra151ns furnd5 urltableoctmtles Membershlp Con8re5S Meetlnis Dntyv4ents PLllc•rionsandlournal% P(Alcyand PubllcAffalrs Natlonal Research wpport P•rtnershlp Educjtkjn ard Caroefs Publk enia8ement CommurnkBriori$ Interna11on work 36 13 13 181 J81 166 25J 377 181 161 118 166 377 176 161 31 87 G2 67 73 73 14G 32 1,602 ?.3 169 32 223 1,827 ri•1 lTrcom•l•xp•ndiiw•I brfor•DIN I￿1￿•￿￿ tr4n•l• Net pIn￿l￿$se$l on In¥eSt￿nts Transfers bemeen funds r4•t h￿rnI 393 359 S07 $07 738 162 736 866 P•tw¢Won ollurtdK' FundsbrO￿htfoIWdrd 3,771 250 57 4,078 FUtyds¢arrfedfo￿1rd 3,933 25 4,944 52

Notes to the flnancial statements 21 Charity statement ol linzntial activltles Unrestrlcted funds General lund5 £'ooo Designated funds £'ooo Restricted funds E'OOO Tot31 2022 £'(N)o Total 2021 E'OOO Income from: Grants and donations Investments Charltable a¢tlvltles Membership Partnership Work Congress Meetings and events Journals Glft Aid and rechar8e from BSI Tradin mlted Totsl In¢om• 284 290 151 190 113 151 160 40 293 li 913 160 40 293 li 913 145 io 44 1,552 353 353 132 1,927 284 2,211 2,186 Expendlture on: Ralsln8 funds Invèstment management fees Cost of rabslng fund5 Charftable actl¥ltl•s Membership Congress Meetln85 and events Publlcations and journa15 Policy and Pltbllc Aflairs Natlonal Research sUPPOrt Partnershlp work EdLgcatlon and Careers Dlver51ty and inclusion Public en8a8ement Communlcatlons Internatlonal work Total expendlture 41 30 41 30 36 13 240 642 184 370 138 181 166 253 377 IBI 161 118 67 642 184 370 175 149 133 198 37 149 133 68 125 115 227 28 2.219 117 227 28 2.537 73 169 32 1,827 125 193 14et Incgme lÈxpendltur•l befo￿ 8alns Ilossesl on Inve5tm•nts and transkrs Net 8ains/llosses1 on Investments Transfers between funds Net iniomelldelicitl 12921 11251 91 13261 359 13051 13051 507 90 15081 90 12151 91 163zI 866 RLondlllon of funds: Funds brou8ht forward 3,933 986 25 4,078 Funds carried forward 3,425 771 116 4,312 4.944 53

Board of Trustees Date of appolntment I resl natlon 2021-22 Board attendance 2021-22 Commlttee attendance Posltlon Current office holder 2021-22 committee5 Forum. Nominations & Congress Commlttee5 Flnance Sub Committee & Con8ress Committee Forum & NoMinatSons Commlttee Forum, ClIni￿1 & Con8re5S Commlttees Appointed Detember 2018 014 Presldent Professor Arne Akbar 414 112 Treasurer Dr Flona Cullev Re-appointed July 2022 414 414 414 Chalr of Forum Professor Ann Ager Appolnted December 2018 414 414 Ill Clinical Secretary PTofeSSOT Colln Dayan Appolnted October 2019 414 V2 ty2 314 Early Career Trustee Early Career Trustee Resl8ned luty 2022 Appolnted Oecember 2018 Appointed October 2016 Appointed July 2019 Appointed Januar 2017 Re-appolnted Jul 2019 Appolnted janua 2017 Appointed Juty 2019 Re-appoinied Ma 2019 Appointed Juty 2022 Appointed Juty 2022 Appointed December 2018 Dr Calum Baln 314 Dr Emma Chambers 012 Co-opted TTU5tee Robert Davles 414 Nominatlons Commlltee ill Professor Deborah Ounn-walters Professor Matthias Eberl Trustee 314 Trustee Nominatlons Commlttee Flnance Sub Commlttee 414 ill Coopted Trustee Dr Paul Hardln8 314 414 Co-opted Trustee Dr Edlth Hessel 414 Ctropted Trustee James Lowe 314 Flnance Sub Commlttee 414 Truslee Professor Allan M¢)wat 414 Earty Career Trustee Dr Matthew SlggSns Co-opted Trustee Dr Sini5a Savi Trustee Or Dlvya Shah 414 Nomlnatlons Commlttee yi 54

Key managemènt personnel Name Position Dr Dou8 Brown Chlef Executlve Otto ealsiger Finance Direttor DT Jennle Evans Dlrector of External Affalr5 lane Sessenwein Head of Evenis & Conferences Luty Mclver Head of PublishinB Prlnclpal profe5s1onal advlsÈrs Namè Posltlon Bank of Scotland 14116 Cock5pur Street London Bankers EC2V 60L Moore Klngston Smlth LLP 9 Appold Street London External audltors EC2A 2AP Abrdn Iformerly Aber(leen Standard Chartered) 14th Floor Investment advisers 30 St MaryAxe London EC3A 8BF Russell Cooke LLP 2 Putney Hill London 5oll¢ltors 5W15 6AB 55

ommittees Nomlnatlons Commlttee Name Poslllon Profe5s0rArne Akbar Chair, BSI President Forum Chair and Trustee Profe5sorAnn Ager Robert D3vle5 BSI Co-opted Trustee Trustee Professor Matthlas Eberl Dr DI￿¥3 Shah Dr Dou8 Brown Trustee B51 CEO lobserverl Finance Sub Commlttee Name Posltlon Dr Flona Cullev James Lowe BSI Treasurer Co-opted Trustee Co-opted Trustee BSI Chlef executlve Paul Hardlt)g Dr Dou8 Brown Otto 8alsl8er BSI Finance Dlrector Forum Name Posltlon Professor Ann A8er PTofe55or Ame Akbar Chalr BS1 Pre51dent Dr Colln Dayan Dr Donald Palmer ClinScèl Secretary Educatlon & Careers Secretary Public Engagement Secretary BSI Chief E¥ecutlve BSI Dlrector of External Affalrs Professor Donald Oavidson Dr Doug Brown Dr Jennle Evans Dr Me8an Macleod Dr Julia Makinde Reglonal Representatlve- Scotland Re8ional Repre5entative- England Re8lonal Rep￿SentatIVe- Northern Ireland Reglonal RepresentatSve- Wales Early Career Representative Early Career Representative Early Career Representatlve Early Career Representative PhD Representatlve PhD Representatlve Industry Representative Cllnical Representative Cllnlcal Representative Veterlnary Representatlve Dr Karlm Dlb Dr SSmone Cuff Dr Loulse Topplng Dr George Robinson Dr Falth Uwadlae Dr Edoardo Prediletto Dr Lauren Campbell Dr Niamh Richmond Dr Federica Villanova Or Matthew Buckland OrTomaz Garcez Dr Elma Tchllian 56

ommittees Congress Commlttee Name Posltion Professor Mark Coles BSI Congress Secretary BSI President Professor Arne Akbar Dr Flona Cullev Dr Colin Dayan Professor Llnda Wooldridge Dr Helen McGettrlck BSI Treasurer BSI Cllnical Secretary Member Member Dr Danlel O'connor Early Career Representstive IE Dr Alexandra Spencer Or Henry Mcsorley Drjohn Tregonlng Drjames Thaventhiran Dr Margarlta OomlnBuez Dr James Harker Dr Graham Cook Member Member Member Cllnlcal member Membef Membef Member Dr Sandra Sacre lane Se5senweln Member B51 Head of Events & Conference5 Cllnlcal Cornmlrtee Name Position Dr Adrian Heaps Dr Rtchard Herriot Assotlatlon foi Cllnlcal Blochem15try Association of Clinical Patholo8lsts Institute of Blomedical Science Dr Chris Scott Dr Tarlq El-shanawanv Dr Stephen Hu8hes Dr 5iraj Mlsbah Dorothea Gr055e-Kreul 8rltlsh Society for Allergy & Clinlcal Immunologv Brftlsh Paediatrl¢ Allergy Immunolo8y & Infectlons Group 5peclal Advlsory Committee on Immuno108y IRCPath SAC) Immunology & Allergy Nurses group TraSnee Rep joint Commlttee on Immunolo8y & Allergy IJCIAI UK Primary Immunodeficlency Network IUKPINI Chalr/ClSnical Secretary BSI Chief Execuilve Dr Kavltha Soorlyakumar Dr Shuaib Nasser Dr Slnlsa Savi¢ Dr Colin Dayan Dr Dou8 Brown 57

ournals Cllnlcltslond Experimenttsllmmunoloqy Editorlal Team Name Posltlon Professor Leonle Taams Editor-in-chief Protes50rAn8elo Manfredi Professor Tanla de Gruijl Professorclrlaco Pi¢cirillo Sectlon Edltor- autoimmvnlty Sectlon Edltor- cancer immunlty Section Edltor- Immune-medlated Inflammalory d15eases Section Editor. Immunodeficlentv Sectlon Editor- infe¢tious diseases and vaccines Section Editor - Infectlous dlsease5 and vacclnÈs Section Editor- neurolmmunolo8V Dr Clndy Ma Dr daniel Douek Professor Xlao-Nin8 Xu Professor $4ndra Amor ImmunotherapyAdvunces . Edltorlal Team Naffle Posltlon Profe550r TIM Elliot Professor Stefan Barth Assoclate Profèssor Marlanne Boe5 Professor Adrlanna 8onomo Editor-ln-chlef Regional Editor.. Afrlca Regional Editor.. Eufope Re8lonal Edltor,. South Amerlca Re8lonal Edltor.. Asi Reglonal Edltor.. North Amerlca Professor Tao Don8 Dr Stephanie K Dou8an Assoclate Professor Menno van Zelm Regional Editor.. Australa51a Dlstoverylmmunoloqy - Edltorlal Team Name Professor Slmon MilllD Dr Awen Gallimore Dr Florent Ginhoux Dr Emll G er Flndlay Professor Kathleen Mcc Dr Lal Guan N Professor Fran¢iKo l. Quintana Dr Meera Ramanulam P051tlon Edltor-ln-chlef Senlor Edltor Senlor Editor Senior Editor Senior Edltor Senlor Edltor Senior Edltor Senlor Ediior

Regional and Affinity groups Affinlty Groups Group Posltlon Chair Professor Lury Walker Autolmmunlty Affinity Group Secretary Dr Kathryn Steel Treasurer Drjarnes Pearson Chalr Wllhelm Gerner Comparatlve Veterlnary Immunology Group Dr Lindert Benedlttus Secretary Treasurer Dr Kate sutton Hlgtorompatlbillty & Immunogenetlcs Group Chalr Professor David Brl88S Dr Luke F05teT Secretary Co-chalr Dr Laura Pallett Co.Chalr Dr Llnda Slnclalr Immunometabollsm Afflnlty Group Secretary Dr Sarah Dlmeloe Treasurer DrAnna Schurich Chalr Dr Slan Henson Immunosenescence Afflnlty Group Secretary Trea5uTer Or NatalSe Rlddell Dr Catarlna Henrlques Infectlon and Immunlt¥ Group Chalr Professor Peter Barlow Inflammatlon Affinlty Group Treasurer Dr Joanne Konkel Communlcatlons Dr Jack Rlvers-Auty Chalr Dr Myrlam Chimen Dr Grneme O'8oyle Leukocyte Mlgratlon Group Secretarynreasurer Chalr Professor Carnien-mollna Parf5 Mathematlcal Modelling Group Secretary Profe550r Mark Coles T￿asurer Professor Grani Lythe Chalr Dr Sarosh Irani Nevrolmmunology Group Secretary Dr Yvonne Dombrowski Chalr Dr Phll Ho8arth Vaccine Affinity Group secretary Dr Julia Tree Treasurer Dr Bernardo Vlllarreal-Ramos Chalr Professor Benjamin Willcox Dr Seth 8. Coffelt Tumour Immunolo8yAfflnlty Group Secretary Treasurer ProfessorAwen Galllmore Co-chabr Professor John C4brrow TeathingAffinlty Group CTr¢halr Dr Nigel Francis 59

egional and Affinity groups Reglonal Groups Group Position Chair Dr Isabel Crane Aberdeen Immunolo8y Group Treasurer Dr Soumya Palllyil Chalr Dr Laura Rivlno Brlstol Immuno108y Group Secretary Dr Dronwen Burton Treasurer Dr Llndsay Nlcholson Cambrldge Immunologv Group Chalr Dr Brlan Fer8uson Secreiarynreasurer Dr Loulse Boyle East Anglia Immun¢lo8y Group Secretary Dr Marla O'connell Treasurer Dr Crlstlna Fanutti C￿ChaIr Oe Ceclle Benezech Ctrchalr Or Laura M¢Cullork Edlnbur8h Immunology Group 5e¢retary Or Matthew Bur8ess Secretary DrTovah Shaw Treasurer Dr Davld Donaldson Chalr Professor Richard Grencls Greater Manchester Immunolobry Group Secretary Dr Ana Vlllegas-mendez Treasurer Dr Joanne Konkel Chalr Dr Kevln Marthbank Immunology North East Secretary Dr Antony Antonlou Treasurer Dr Andy Knight Chalr Dr James Harker London Immunology Group secretary Dr Laura Pallett Treasurer Dr Allce Burton Merseyside Immunolo8V Group Secretary Dr Qlbo Zhang Treasurer Dr Steve Christmas Chalr Dr Alexandra spencer Co-5ecretary Dr Loulse Johnson Oxford Imrnunology Group CTrSecretary Dr Anita Milicic Treasurer Dr Phllipp Kruger

e8ional and Affinity groups Rexional Groups Group Position Chair Dr You Zhou DT Rebe(c3 Alcheler Dr Ceri Fieldihg Professor Simon Arthvr South Wales Immunology Group Secretary Treasurer Chalr Tayside Immunology Group Secretary DT Mahima Swamv Treasurer Dr Stephen Matthews President Dr Yvonne Dombrow5ki Ulster Immunology Group Secretary Dr Karim Dlb Chalf Dr Emma Re￿e5 Wessex Immuno108y Group 5ecretsry Dr Allson Hlll Treasurer Dr Dlogo Sllva Co-chalr Dr Davld Bentllng West Midlands Imrnuno108y Group Co-chalr Dr Kendle Ma51owskl Secretary Dr Lla Llaskou Treasurer Drzhiu Chalr Dr Me8an MacLeod DT Ed Roberts West of Scotland Immunolo8v Gioup Secretary Treèsurer Dr Hannah Scales Chalr Dr Glna Doodv Yorkshlre Immunolo8y Group Secretsry Dr Erlca W1150n 61